




Prostate Cancer
Foundation
Curing Together.

A dark blue horizontal band with a white network graphic of interconnected nodes and lines.

The Next 25 Years

Beginning the End of Cancer

2018–19 Progress Report



Prostate Cancer
Foundation
Curing Together.

ABOUT THE COVER

PCF's research is responsible for catalyzing progress across innovative treatments that were not available 25, 10, or even 2 years ago – including gene targeted therapies, immunotherapy, radiopharmaceuticals, and microbial transplants. The next 25 years will see rapid change in the way we view and treat cancer.

The Next 25 Years Beginning the End of Cancer

MISSION STATEMENT

PCF funds the world's most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.

BEGINNING THE END OF CANCER

25 years at the forefront of bleeding edge cancer research affords a lot of perspective. With more than 1.5 million more men alive today because of PCF's innovative cure model, we have earned the right to look forward, and here's what we see: **this is the beginning of the end of cancer.**

It has been a long fight – a valiant fight – with many plot twists and turns. So, you might ask, what's suddenly different?

Investments in big data and global information sharing are bringing together great minds to collaborate in ways they never could have imagined. This convergence allows PCF not only to learn from research across all cancer, but to bring treatments to market that go beyond prostate cancer and into more than 73 other forms of human cancer.

The fight is not over, but inside you'll find many of the reasons why we think the final chapter has begun.



PCF meets all 20 of the Better Business Bureau's standards for charity accountability.



PCF has been designated a Top-Rated Charity by Charity Watch.

The Flexibility to Fail: A New Way to Succeed in Cancer Research A Message from our Chairman and CEO	4
PSMA Theranostics: “If We Can See It, We Can Treat It”	7
Many vs Cancer 2018 Impact: The Power of Many	10
PCF+Fuego Box: How a Spicy Chocolate Bar is Saving Mankind	12
2nd Annual PCF <i>TRUE Love</i> Campaign	14
PCF Partners With the Atlanta Hawks for Black History Month Assist Challenge	15
NIH and PCF Partner to Launch Research Study on Prostate Cancer in African American Men	16
New Game-Changing Drugs for Advanced Prostate Cancer	18
The John and Daria Barry Foundation Precision Oncology Center of Excellence at the VA New York Harbor Healthcare System	20

The Next 25 Years Beginning the End of Cancer

2018 PCF New York Dinner at Daniel	21
The Movember Foundation and PCF Celebrating More Than a Decade of Partnership	22
The Inaugural Jerry Weintraub Celebrity Pro-Am Golf Tournament	23
Another Year Around the Bases for the 2018 Home Run Challenge	24
Never Give Up: The Journey From Metastatic to Complete Response	26
Supporting Cures	29
2018 Donor Roll	30
2018 Research Awards Expanding PCF’s Global Research Enterprise	36
2018 Financials	42
2018 Supporting Partners	46
Board of Directors and Leadership Team	47

The Flexibility to Fail

A New Way to Succeed in Cancer Research

Dear friends,

In 1993, nearly 35,000 men in the United States died from prostate cancer. If you had advanced disease, there were few treatments available, and even those men whose disease was caught early suffered major and sometimes permanent changes in quality of life for both themselves and their families.

Today, thanks to your support and 26 years of cutting-edge research by the Prostate Cancer Foundation, life for men with prostate cancer looks entirely different. There are more than 20 drug choices available for men with advanced disease, and many more treatment options are in the pipeline. Without the rapid-funding model pioneered by PCF, many of these discoveries might still reside in research rather than in clinical settings.

Here are 10 more revolutionary ways PCF continues to shake things up in the research world so that we can catalyze progress, innovate, and deliver the best treatments for patients and families:


1. We actively bring together the world's best and brightest, working on the most promising ideas.
2. We lead prostate cancer out of the shadows and into the forum of public discussion.
3. We actively require researchers to share unpublished data with each other.
4. We have been transparent with every dollar we spend – even before transparency was trendy.
5. We have always given scientists the flexibility to fail in order to succeed boldly.
6. We reward nimble, entrepreneurial behavior and speed progress.
7. We fund interdisciplinary teams of scientists – across institutions and continents – who make innovative drugs that drug companies couldn't even conceive of.
8. We invest in brilliant, yet unknown, young researchers with the most game-changing ideas and fearless drive to help patients.
9. We attract and catalyze mutually beneficial partnerships among government, biopharma, academia, and other foundations.
10. **We've begun to democratize the delivery of precision healthcare.** For all the problems the internet has created for medicine – not the very least of which is the dissemination of false information – there's one amazing feature that supersedes all of its shortcomings combined: PCF has been able to scale and speed the development and delivery of precision treatments to patients. We can now put the best, most accurate "PCF-blessed" information about care options directly into the hands of patients who previously might not have had access.

PCF has always approached prostate cancer as a disease that affects families: caring for men with prostate cancer means looking out for the entire family. Thanks to prostate cancer research that you have funded, we now know that some of the most aggressive prostate cancers are based on genetic mutations that cross over to other forms of cancer. Just one example: if you have prostate cancer, your daughter may be at increased risk for breast cancer. That's critical information for patients and families to know, and crucial work for PCF to fund.

Here are 10 of the top investments from the PCF Research Enterprise that promise to make a difference in prostate cancer patients' lives in 2019 and beyond:

1. **Precision Radiopharmaceuticals.** PSMA is a protein that lives on the surface of all prostate cancer cells, and we're learning how to use it as a homing device. PCF is studying radioactive molecules which, when injected into the bloodstream, can seek out and destroy dangerous cancer cells while leaving normal cells alone.
2. **Checkpoint Immunotherapy.** PCF was an early supporter of Nobel Prize winner Jim Allison's work to bring checkpoint immunotherapy to solid tumors. The full benefit of this critical immunotherapy has yet to be seen in prostate cancer, so look for more trials on the horizon.
3. **Natural Killer Cells.** NK cells, i.e. natural killer cells, can kill thousands of chemotherapy-resistant cancer cells (many more than a CAR-T cell can). They are part of the innate immune system, traveling around the body taking out "stressed" cells, such as cancer. PCF researchers are looking at cost-effective ways to isolate, grow, and transfer colonies of these cells – in a directed way – into the body. Our aim is to genetically engineer or "program" these cells to better target cancer.
4. **Microbiome.** There are 30 trillion cells in your body, but there may be as many as 100 trillion microorganisms living in and on your body. Science is revealing that for cancer treatment (particularly immunotherapy) to be maximally effective, the 100 trillion organisms – referred to as your microbiome – must be in harmony. PCF is investing in precision nutrition research to optimize the care and feeding of your microbiome.
5. **Dark DNA.** For years scientists have been focusing on the "hardware" of cancer: the genes themselves. Dark DNA refers to the software that runs the system; it is inherited from your parents and provides scientists with clues to which people may be more likely to develop cancer. Researchers are discovering that they can do more damage to cancer by tweaking the software code rather than the hardware itself.
6. **Microelectronic Noses that Sniff Out Prostate Cancer.** Dogs are able to smell prostate cancer at a sensitivity that is 10 times more effective than our current PSA blood test. PCF has teamed with scientists at MIT to investigate the possibility of developing a robotic nose to detect prostate cancer at a very early stage.

PCF RESEARCH IMPACTS 73 CANCERS



Areas Affected

▶ Brain	▶ Skin
▶ Eye	▶ Nerve
▶ Lip	▶ Blood
▶ Neck	▶ Sarcoma
▶ Thyroid	▶ Prostate
▶ Esophagus	▶ Testicle
▶ Thymus	▶ Breast
▶ Lung	▶ Cervix
▶ Liver	▶ Ovary
▶ Stomach	▶ Uterus
▶ Gallbladder	▶ Childhood Brain Cancer
▶ Pancreas	▶ Childhood Blood Cancer
▶ Kidney	▶ Childhood Kidney Cancer
▶ Colon	
▶ Bladder	
▶ Rectum	

7. **AI for Big Data at the VA.** Prostate cancer is the most common disease among our nation's heroes: veterans. PCF and the VA are partnering to prevent, screen, and promote research to speed the development of treatments and cures for prostate cancer among veterans. The wealth of electronic data collected in this program will have an extraordinary impact across the entire field of prostate cancer research – involving hundreds of thousands of patients – and beyond.
8. **Neuronal Protection to Reduce Erectile Dysfunction.** Trauma to the body can cause tissue damage. Fortunately, with prostate cancer surgery, we know when the trauma is going to take place (unlike, say, in the case of a stroke), and we know exactly what tissue area will be affected. Researchers are looking into what preventive action might be taken to strengthen and preserve the nerves around the penis before surgery.
9. **Liquid Biopsy.** A PCF Challenge Award team is developing a “liquid biopsy” blood test to assess tumor mutations, replacing the need for invasive, painful, and expensive biopsies of tumors. Results from this test could revolutionize predictions of tumor recurrence and patient prognosis.
10. **Precision Treatment Across Cancer Types.** Unique cancers in unique patients require unique cures. The recent advent of affordable genetic sequencing panels, combined with the cutting-edge innovations listed above, means that the research that PCF has been doing for years – to identify gene targets and develop targeted treatments for prostate cancer – can finally be put to good use. It also means that a drug developed for prostate cancer could be equally useful, if not more so, in colon, breast, lung, or any number of other cancers and has the potential to impact millions of lives.

Twenty-six years ago when PCF was launched, many of the ideas above might have been found in a sci-fi movie. Today and in the years to come – thanks to your generosity – we're seeing medicine so revolutionary that science is finally catching up to our imaginations.

The complete elimination of death from prostate cancer continues to be our goal, and we are in a race against time for every patient and his loved ones. New treatments are on the horizon, but we still need your help to finish the job. With your support and the innovative ideas of brave investigators that have led us this far, we are hopeful that we will extend and save the lives of millions.

With gratitude,



Michael Milken
Founder and Chairman




Jonathan W. Simons, MD
President and Chief Executive Officer




PSMA Theranostics

“If We Can See It, We Can Treat It”

What is Theranostics?

Theranostics is a new field of medicine that combines specific targeted therapies based on specific targeted diagnostic tests. With a key focus on patient-centered care, theranostics provides a transition from conventional medicine to a contemporary, personalized, and precision medicine approach.



The theranostics paradigm involves using nanoscience to unite diagnostic and therapeutic applications to form a single agent, allowing for diagnosis, drug delivery, and treatment response monitoring.

PSMA (prostate-specific membrane antigen), is a protein that is expressed on the surface of prostate cancer cells. Because of its properties, PSMA is considered one of the most promising targets for both imaging and treating prostate cancer. **PSMA theranostics** is an emerging field of medicine that combines precise imaging and very specific therapy, using the same molecular target – and the Prostate Cancer Foundation has been involved in this exciting research from the very beginning.

In 1996, PCF-funded scientist and Weill Cornell Medicine physician Neil Bander, MD created an antibody that can target PSMA, and in a series of clinical trials, demonstrated that when attached to a radioactive molecule, this agent could be used to both image and treat prostate cancer. In 2002, a Johns Hopkins team led by another PCF-funded investigator, Martin Pomper, MD, PhD, developed a similar weapon: a PSMA-targeting small-molecule imaging agent. In 2011, with PCF and Movember funding, Pomper's colleague, Steve Cho, MD, now at the University of Wisconsin, led the first human PET imaging study using Pomper's agent and found that it was especially good at picking up high-grade Gleason tumors within the prostate – something that men considering active surveillance or treatment for localized cancer really need to know.

Since then, PSMA-PET imaging using a derivative of this small molecule, ^{18}F -DCFPyL, also developed by Pomper, and with a similar agent developed at the University of Heidelberg in Germany, ^{68}Ga -PSMA-11, has been shown to outperform all standard imaging methods for detecting metastatic prostate cancer. These tests can identify very small sites of metastasis that may not show up on CT or bone scans. The ability of PSMA-PET to detect metastatic or recurrent disease earlier could shift additional treatment earlier, as well. Depending on whether the spread of cancer is localized, “oligometastatic” (just a few spots of cancer outside of the prostate), or more widespread, treatment may be aimed at specific locations – via salvage radiation, salvage pelvic lymph node removal, or stereotactic body radiation therapy (SBRT) – or may involve systemic therapy.

For example, Johns Hopkins University radiation oncologist and PCF-funded investigator Phuoc Tran, MD, PhD, hypothesizes that in men with oligometastasis, by treating “not only the primary disease in the prostate or the pelvis, but also the few metastatic lesions, perhaps men can actually live a long time without disease progression, and might even be cured.” Using PSMA-PET to show spots of cancer



Neil Bander, MD
Weill Cornell Medicine
*9-time PCF Competitive Award recipient,
1993-2001*



Martin Pomper, MD, PhD
Johns Hopkins Medicine
*PCF Challenge Award recipient, 2012;
PCF-Movember Foundation Challenge
Award recipient, 2014*



Steve Cho, MD
University of Wisconsin
Carbone Cancer Center
*Class of 2008 PCF Young Investigator;
PCF-Movember Foundation Creativity
Award, 2011*


as small as a few millimeters, SBRT can deliver “highly focused radiation given in an intense fashion,” Tran says. “I tell patients it’s like spot welding: focused on a small area, very intense, and theoretically ablative, meaning it kills all the cancer in that spot.” Tran is testing this hypothesis in a randomized clinical trial.

PCF-funded investigators including Kenneth Pienta, MD, Steven Rowe, MD, PhD, and Mark Markowski, MD, PhD, of Johns Hopkins University; Michael Morris, MD, and Steven Larson, MD, of Memorial Sloan Kettering Cancer Center; Steve Cho, MD of University of Wisconsin; Mark Preston, MD, of Harvard Brigham and Women’s Hospital; Thomas Hope, MD, of the University of California, San Francisco; and Johannes Czernin, MD, of the University of California, Los Angeles, are now leading pivotal registrational clinical trials for the PSMA-PET imaging agents ^{18}F -DCFPyL and ^{68}Ga -PSMA-11. It is likely that FDA approval will be granted in the very near future for these agents.

Equally exciting, is that when PSMA-targeted agents are hooked up to more powerful radioactive isotopes (those that emit DNA-damaging alpha or beta particles), they become potent cancer therapies. **PSMA-targeting radionuclides** can bring a high dose of radiation directly to cancer cells anywhere in the body, with the potential to kill them. Several different PSMA-targeted radionuclide therapies developed by PCF investigators and others are being tested in clinical trials for prostate cancer. Early reports on these treatments have been highly promising. Radionuclides using Bander’s antibody (J591) for instance, have demonstrated both safety and promising efficacy and continue to be tested in several trials. Another of these agents, ^{177}Lu -PSMA-617, cut PSA levels by half or more in 62% and 33% of patients in two separate Phase II clinical trials led by PCF-funded investigators Michael Hofman, MD, at Peter MacCallum Cancer Centre in Australia, and Jeremie Calais, MD, at the University of California, Los Angeles, respectively. In these trials, ~10%-15% of patients were considered “exceptional responders,” with PSA or tumor burden going almost entirely to zero, although no patients were cured. ^{177}Lu -PSMA-617 has now advanced to testing in an international, multicenter, randomized Phase III trial.

PCF is funding numerous investigations into developing and optimizing this new class of treatments, testing them in combination with other treatments and identifying which patients are most likely to benefit and why. PSMA-PET imaging, as it turns out, is likely ideal for identifying which patients are more likely to respond to PSMA-targeted therapies, and is being used to select patients for clinical trials. As Howard Soule, PhD, Executive Vice President and Chief Science Officer of PCF, puts it: “If we can see it, then we can treat it.”

Radioactive isotopes are not the only payload that can be delivered directly to prostate tumors by PSMA-targeting agents. PSMA-targeting treatments that deliver cancer-killing immune cells or chemotherapy are also being developed. For instance, PSMA-targeted CAR T cells have been developed by PCF-funded investigators at the University of Pennsylvania and are now in Phase I clinical trials.

Over the past 25 years, PCF has invested more than \$15.8 million in investigations into PSMA as a target for prostate cancer treatment or imaging. 



Prostate
Cancer
Foundation



Curing Together.

Many vs Cancer

Through this grassroots group of caregivers, survivors, family, friends, and fighters, we have raised more than \$1.5 million to defeat prostate cancer once and for all.

One observation we often hear from families who have been affected by cancer is “I feel powerless against this disease. What can I do to help?” Many vs Cancer was founded on the idea that anyone and everyone can make a difference in the fight against cancer. MvC helps bring awareness to each of our social circles and provides easy to use tools to activate your network in support of prostate cancer research. To date, funds have been raised from efforts like backyard parties, lemonade stands, running, cycling, and other events like the PCF Pushup Challenge.

Please visit manyvscancer.org today and join our community.

Here are some of our superstar fund raisers for 2018:



Ramiro Siliezar

Ramiro is an LA-based custodian with a passion for running. After his twin sister was diagnosed with BRCA+ breast cancer, Ramiro decided to dedicate his runs to her and to start fundraising for cancer research. When he learned that the BRCA gene is also an area of focus for the Prostate Cancer Foundation, Ramiro joined Many vs Cancer and started inviting friends, family and local business professionals to support him. To date, he has run over 1,000 miles for PCF, raising nearly \$70,000.

David Frantz (pictured left)

David, a retired high school golf coach, was voted “Coach of the Year” three times, but he could have never anticipated that he and his older brother, Will, would both be diagnosed with prostate cancer. Will lost his life to the disease, which lit a fire under Dave to help fund PCF’s research. While getting ready to undergo surgery, Dave set up his page and rallied friends together to raise more than \$2,400.



Milton High School Cross Country Team

Each year, the Milton High School Cross Country Team tasks its captains with selecting a charity to support. After learning that one of their coaches and two fathers of team mates were diagnosed with prostate cancer, it was an easy decision. The team raised \$7,159, beating their \$7,000 goal. Go Eagles!



Steven Malikowski

Steven, a former Education Program Specialist with the Department of Family Medicine and Community Health at the University of Minnesota, is living with advanced prostate cancer and being treated with a drug that was developed with PCF funding. He wanted to give back to the Foundation and his lifelong dream has been to cycle across the continental U.S. This year, he did it! Starting at the Virginia coastline, Steven cycled over 4,100 miles, crossing mountains, plains and everything in between. After four months on the road, he dipped his front tire in the Pacific Ocean and celebrated the completion of his ride. Through his journey, Steven raised more than \$4,500.




*It takes more than one person to end prostate cancer.
It takes **many.***

FUEGO BOX + PCF

How a Spicy Chocolate Bar is Saving Mankind



Fuego Box, the world leader in craft hot sauce subscription boxes, specializes in curating and delivering the most delicious and hard to find hot sauces to chili heads around the world. After successfully launching a Father's Day Gift Box benefitting PCF in 2018, Fuego Box realized that their customers (and prospective customers) care about prostate cancer and were responding to the company's support of men's health. Building off this success, Fuego Box's Founder and Co-Owner, Mike McAdams, partnered with PCF to launch *The Choco Challenge*.



The Choco Challenge

The concept was simple, elegant, effective, and fun: Create the world's spiciest mini-chocolate bar and then challenge the public to purchase the bar and film themselves eating it – with \$5 of every purchase donated to PCF.

Why it Worked


The internet is rife with “spicy challenges”, but this was the first time that one incorporated a charitable cause and included a men's health education and awareness message. Many responded to the “dare” of eating something so spicy, while many others tuned in for the entertainment and schadenfreude of watching someone take the challenge.



PCF Director of Corporate Development, Oliver Freund (center) is presented with a donation check for \$125,000 by Fuego Box founder, Mike McAdams (right) and Operations Manager, Teddy Wilkins (left).

The Results

- ▶ More than 27,000 *Choco Challenge* bars sold to spice seekers around the world
- ▶ \$135,000+ raised in support of PCF's mission
- ▶ \$205,000 value of earned media coverage reaching more than 6 million consumers
- ▶ 27,000+ *Choco Challenge* participants educated about prostate cancer via inclusion of PCF's messaging and educational content with every package sold
- ▶ Due to the viral nature of spicy challenges, the top 7 *Choco Challenge* videos alone generated more than 8 million views.
- ▶ User generated videos created and shared across social media platforms were viewed by millions of people, gaining the attention of mainstream celebrities and prime time television.
- ▶ Through 10,000+ videos, challenge takers were dedicating their *Choco Challenge* to fathers, uncles, and grandfathers affected by the disease, with many noting that a few minutes of pain was nothing compared to battling a prostate cancer diagnosis.
- ▶ The campaign went viral, catching the eye of several mainstream celebrities. Of note, Shaquille O'Neil highlighted the challenge on *Inside the NBA*, and Kristen Bell and Dax Shepard had their *Choco Challenge* video featured on *The Ellen Show*.



Key Learning: Doing Good is Good for Business

The lesson here is that PCF is always ready for the next innovative idea to share our message and engage the public in a conversation about prostate cancer. We can “do good” for our research mission while also supporting the business and marketing goals of our partners.

Does your company want to join us in our mission? Get in touch with us and we can build the next head-turning, high-impact campaign together!

2nd Annual *TRUE* Love Campaign



“*I am honored to support the Prostate Cancer Foundation with their **TRUE Love** contest honoring caregivers in the month of February. Their selflessness and hard work is so admirable and I wanted to give love and recognition to all of these unsung heroes over this Valentine’s season.*”

— Kristen Bell

In February 2019, PCF celebrated the 2nd Annual month-long **TRUE Love** campaign and contest that honored caregivers for their tireless work in caring for loved ones living with prostate cancer.

The campaign was designed to drive greater awareness of PCF by exposing us to new audiences. **TRUE Love** is a tribute to the unsung heroes – spouses, partners, nurses, doctors, siblings, children, and friends. PCF accepted “**TRUE Caregiver Stories**” from all perspectives that reflected love, honor, and care for prostate cancer patients throughout the Valentine’s season when love is celebrated. Those with the most inspirational stories won a special care package personally curated by award-winning actress Kristen Bell, who also served as the spokesperson and face of the campaign.

Kristen, known for her accomplished work in *Veronica Mars*, *Frozen*, and *Bad Moms*, helped create awareness about the **TRUE Love** contest and how a prostate cancer diagnosis affects the entire family. The cause hit close to home for Bell. Her mother is a nurse, and her father-in-law fought prostate cancer and has sadly passed away after a multi-year battle. She understands first-hand how caregivers are an essential part of a support system and how they often lack support and are underacknowledged, compared to caregivers of other diseases. PCF and Kristen changed this narrative by sharing **TRUE** inspirational stories of the people who live **TRUE Love** everyday by providing care to men – many who have debilitating metastatic disease.

We are so grateful to Kristen for helping us raise awareness about prostate cancer with this campaign. Her generosity, authentic compassion, and broad reach played an integral part in the campaign’s success and also helped shine a spotlight on all the resources we have available for patients and their caregivers.



\$150,000
TOTAL
DONATION

6M+

FAN IMPRESSIONS



902

RADIO SPOTS



791
TV SPOTS

105

NEWS HITS
AROUND THE
WORLD



295

TOTAL ASSISTS
IN FEBRUARY

93,296

VIDEO VIEWS
ON SOCIAL MEDIA



PCF Director of Corporate Development, Seth Swerdlow is presented with a donation check for \$150,000 by Atlanta Hawks NBA team part-owner and Vice Chair, Grant Hill for a successful first-year Black History Month Assist Challenge.



Prostate Cancer
Foundation
Curing Together.

Black History Month Assist Challenge

February 2019 launched the first-ever Black History Month Assist Challenge. The Atlanta Hawks teamed up with PCF to be the first NBA team to bring the disparity of prostate cancer rates in African American men to center court.

The Atlanta Hawks donated \$250 to PCF for every assist they made in the month of February to fund research that will address the fact that African American men are 76 percent more likely to be diagnosed with prostate cancer, and more than twice as likely to die from the disease.

The spotlight the Atlanta Hawks shined on prostate cancer dramatically increased awareness of this disease. Life-saving information about risks and screening reached more than 120,000 people during the 12 NBA games they played in February and reached hundreds of millions more through digital outreach. Thanks to the Atlanta Hawks, more men of all ethnicities will be screened this year, know their risks, and get the early treatment they need.



NIH and Prostate Cancer Foundation Launch Large Study on Aggressive Prostate Cancer in African American Men

July 2018 – The NIH and the Prostate Cancer Foundation have partnered for the largest coordinated research effort in history. The RESPOND study, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress, will study how biological and non-biological factors contribute to African American men being diagnosed with prostate cancer at alarmingly high rates relative to other ethnic groups. The reason these disparities exist is a critical unanswered question in cancer research.



RESPOND

African American Prostate Cancer Study


“No group in the world is hit harder by prostate cancer than African American men, and, to date, little is known about the biological reasons for these disparities, or the full impact of environmental factors. We celebrate our partnership and applaud NIH for spearheading this study, which we believe will help pave the way for groundbreaking discoveries that will improve health equity for African American men and their families.”

— Jonathan W. Simons, MD
President & CEO, Prostate Cancer Foundation

African American men are 76% more likely to be diagnosed with prostate cancer, are more likely to develop an aggressive, quickly progressing form of prostate cancer, and are 2.2 times more likely to die of prostate cancer than men with other ethnic backgrounds.

This \$26.5 million study will aim to enroll 10,000 African American men with prostate cancer into the RESPOND study. Investigators in the study will examine possible associations between aggressive disease and exposures to neighborhood/environmental stressors such as discrimination, early-life adversity, and segregation. They will also study DNA and tumor samples to identify gene variants associated with aggressive prostate cancer. Once researchers have identified genetic changes associated with aggressive prostate cancer, they will investigate how the social environment interacts with those genetic changes.

RESPOND is supported by the National Cancer Institute (NCI) and the National Institute on Minority Health and Health Disparities (NIMHD), both parts of the National Institutes of Health, as well as by the Prostate Cancer Foundation (PCF). The NCI funding will be provided from the 21st Century Cures Cancer Moonshot Initiative.



Drs. Christopher Haiman and John Carpten of USC are two of the many investigators engaged in the RESPOND African American Prostate Cancer Study.

The RESPOND study is supported by the National Cancer Institute and the National Institute on Minority Health and Health Disparities of the National Institutes of Health, under grant number CA214253 and by the Prostate Cancer Foundation.



New Game-Changing Drugs for Advanced Prostate Cancer

Until recently, androgen deprivation therapy (ADT) alone was the front-line treatment option for men with advanced prostate cancer. Unfortunately, nearly all patients will eventually become resistant to ADT, creating an urgent medical need for new treatments.

Fortunately, due in large part to PCF's funding of crucial basic science research and the early steps of new drug development, the treatment landscape has rapidly evolved over the last two years, with a slew of clinical trials demonstrating that using stronger therapies earlier can be extremely beneficial.

There are now 5 new treatments that demonstrate significant survival benefit or disease progression slowing when used before ADT resistance develops. These include docetaxel chemotherapy and four "second-generation" hormone therapies – abiraterone, enzalutamide, apalutamide, and darolutamide. PCF-funded research pivoted the development of all of these treatments.

Two categories of advanced prostate cancer have benefited from these new therapies:

- 1 **Metastatic prostate cancer that has not yet been treated with ADT (aka metastatic "hormone-sensitive" prostate cancer, mHSPC)**
- 2 **Non-metastatic castration-resistant prostate cancer (nmCRPC), a clinical state of rising PSA after ADT and before clinical metastasis is detectable**

In mHSPC, the addition of abiraterone or docetaxel at the time men start ADT extended their lives for an average of 17 months in men with high-risk or high-volume metastatic disease. In 2018, the FDA approved abiraterone for men with high-risk mHSPC who were starting ADT. In early 2019,

clinical trial results show that enzalutamide and apalutamide are also effective for mHSPC, and FDA approval is now being sought. It is premature to know which of these treatments is most effective. PCF is funding precision treatment research to answer this question.

nmCRPC was previously a treatment desert without life-prolonging treatments available. These men typically had no other option but to continue taking ADT, despite its diminishing benefit. In 2018, the FDA approved apalutamide and enzalutamide for men with nmCRPC, in combination with ADT. On the horizon is a third option: darolutamide, as results from a Phase III trial have recently been reported as positive. Each of these treatments, when added to ADT, has been shown to delay the onset of metastases by an average of 22–24 months. It is still too early to know if the addition of any of these treatments to ADT in nmCRPC extends survival, but early results hint in that direction.

We at PCF are particularly proud of these new additions to the arsenal of precision treatments for advanced prostate cancer because we helped get these drugs developed. PCF funded the seminal discovery that second-generation hormone therapies could be effective in ADT-resistant prostate cancer – a finding that inspired their development. PCF funded the initial biology and chemistry of both enzalutamide and apalutamide and their early preclinical studies. PCF was instrumental in funding the early stage trial that led to the development of abiraterone, and eventually its FDA approval in 2011. PCF also funded the therapy consortium that conducted early clinical trials for docetaxel which led to its formal development and FDA approval in 2010. We continue to fund research with the promise of finding even more effective treatments for advanced prostate cancer.

“These are very dramatic findings for improving patient care,” says scientist Howard Soule, PhD, PCF’s Chief Science Officer, who directs PCF’s worldwide research programs. However, he adds, “the work is far from over. Every day, men are still dying of prostate cancer. This is why we fund research: to discover cures and to improve quality of life.” 🍷

The John and Daria Barry Foundation Precision Oncology Center of Excellence at the VA NY Harbor Healthcare System Manhattan Campus



For their groundbreaking philanthropy, the Barry Family accepted a special award and honorary doctors' coats representing the sacred trust between doctor and patients.

Left to right: James Barry, Elizabeth Barry Swanson, John Barry, Daria Becker Barry, Deborah Scher, Martina Parauda, Daria Morgan Barry, and Matthew Barry.

Through the generosity of the John and Daria Barry Foundation, PCF's partnership with the Department of Veterans Affairs continues to expand. On November 8, 2018, PCF held a VALOR Dedication Ceremony honoring hundreds of thousands of courageous veterans living with prostate cancer. During the ceremony, PCF president and CEO, Dr. Jonathan W. Simons, recognized the John and Daria Barry Foundation's transformational gift of \$2.5 million to PCF to establish the John and Daria Barry Foundation Precision Oncology Center of Excellence at the Manhattan Campus of the VA NY Harbor Healthcare System (VANYHHS). This center will address the clinical needs of veterans currently battling prostate cancer in the New York metropolitan area and beyond, delivering precision treatments that are tailored to each patient's care based on a genetic understanding of their disease. This best-in-class care will be made accessible to veterans to honor the sacrifice of those who have served. The precision oncology and genetic counseling that will be provided in Manhattan will help lead to better treatments and cures for all veterans. This research will advance critical scientific knowledge with broad implications for the medical research community's ability to deliver life-saving precision treatments and cures to cancer patients globally.



During the ceremony, Director of the VANYHHS, Martina Parauda, graciously acknowledged U.S. veterans in attendance for their years in service.



The VALOR Dedication Ceremony opened with the National Anthem performed by Sergeant Constance Campbell to honor America and the military veterans in attendance.



On behalf of the Secretary's Center for Strategic Partnerships, U.S. Department of Veterans Affairs Executive Advisor to the Secretary, Deborah Lafer Scher made special remarks.

2018 PCF New York Dinner at Daniel



The 2018 Daniel Dinner marked our seventh dinner at the famed Daniel Boulud New York restaurant. Held biennially, the dinner only accommodates 130 people and is a much more intimate experience than our larger New York dinner held on alternate years. Having now established such a long and close relationship with Chef Boulud, he takes great pride in personally creating a special menu for our guests that never disappoints.

The dinner provides an unusual, up-close-and-personal experience with our entertainment. In 2018, The Evasons, a mentalist husband and wife duo wowed our guests with their mind reading skills and powers of perception. Our special musical performer was Pat Benatar.

The legendary singer, songwriter, and actress, is the recipient of 4 Grammy awards and has 2 multi-platinum albums, 5 platinum albums, 3 gold albums, and 15 Billboard Top 40 singles in a career that spans nearly 40 years.

The evening also focused on additional funding of PCF Young Investigator Awards, Challenge Awards, and establishing additional Centers of Excellence in association with our partnership with the VA. The evening successfully brought in more than \$8 million, including \$5 million for 2 new Centers of Excellence and more than \$2 million in new Young Investigator and Challenge Awards.



Front left to right: PCF's New York Dinner at Daniel honored donors to PCF's VA partnership program, John and Daria Barry; Pat Benatar provided a powerhouse performance to close the night; PCF Chairman Mike Milken lead the auction to fund vital prostate cancer research projects.



MOVEMBER® FOUNDATION



CELEBRATING MORE THAN A DECADE OF PARTNERSHIP

Since 2007, the Movember Foundation has generously donated \$56 million to PCF to support 45 research awards in the U.S., Canada, and Great Britain. We are honored to be in the second decade of this incredible partnership which has led directly to many life-prolonging and life-improving oncology developments.

Thanks to Movember funding:

- More than 70 clinical trials testing new prostate cancer treatments and imaging technologies have been initiated
- Clinicians have developed the science and technology necessary for conducting precision medicine in men with metastatic prostate cancer
- New precision medicine treatments have been discovered for patients who have DNA repair gene mutations in their tumor
- The discovery that inherited DNA repair gene mutations increase risk for prostate, breast, ovarian, and other cancers, has led to precision genetic counseling for family members of men with prostate cancer
- A more sensitive new imaging technology, PSMA-PET, has been developed for visualizing prostate cancer recurrences earlier
- Many new drugs have entered the R&D pipeline for treatment-resistant prostate cancer



Movember Foundation Global Action Plan Program Manager, Mark Buzzza (seventh from left), and Executive Director of Programs, Paul Villanti (second from right), poses with recipients of the 2018 Movember Foundation-PCF Team Science Challenge Awards at PCF's 25th Annual Scientific Retreat in Carlsbad, CA.

- Biomarkers, including AR-V7, have been discovered that help doctors to choose the most appropriate treatments for patients
- Blood tests are being developed to analyze tumor mutations so that patients can avoid invasive biopsies of metastatic disease
- Clinical trials are testing new combination treatment strategies that may enable cures in men previously considered to be incurable
- New prostate cancer immunotherapies are being developed, including engineering a patient's own immune cells to fight their cancer

PCF is incredibly grateful to the Movember Foundation for this invaluable partnership.

The Inaugural Jerry Weintraub Celebrity Pro-Am Golf Tournament



In December 2018, a not so extravagant, but certainly not subdued party lit up the night and danced on the links of the Madison Club in La Quinta, CA. The event honored a man who not only survived prostate cancer, but generously funded life-saving prostate cancer research. That

man was Jerry Weintraub.

His calling wasn't to promote or manage great musical talent, or produce and direct Hollywood hits... that was

his illustrious career. No, his calling was to serve as a lightning rod, bringing joy and building sacred bonds with everyone he met. Regardless of when they parted company, meeting up with Jerry meant tapping straight into that joy as if no time had passed.



Cedric the Entertainer on the course with Jerry's son and Tournament Host, Michael Weintraub.



Alfonso Ribeiro showed off some skills during the Awards Presentation at the Madison Club.




The winning team shows off their Vino Trophies. From left to right: Jason Scheff (from the band Chicago), Vince Taormina, PGA Tour Professional Esteban Toledo, Joel Farkas, and his wife Dana (not pictured, Harold Rippis).

The inaugural Jerry Weintraub Celebrity Pro-Am brought out Hollywood celebrities, musicians, active and retired professional athletes, and terrific PGA Tour talent, young and old, to join incredibly supportive donors for a two-day affair never to be forgotten.

Here's to Jerry and his legacy of giving!

Another Year Around the Bases



2018 marked Major League Baseball (MLB) and PCF's 23rd season partnering together for the annual Home Run Challenge (HRC) to defeat prostate cancer. Since 1996, this campaign has raised more than \$47 million to fund prostate cancer research and has helped reduce the U.S. prostate cancer death rate by more than 50% since its inception. All 30 teams participate annually to help raise funds for our cutting-edge research and bring awareness to the journey ahead to defeat prostate cancer.

PCF Chairman Mike Milken shares some pre-game field time with Seattle Mariners outfielder, Ichiro Suzuki and Mariners owner, John Stanton during the 2018 HRC-Seattle tour stop. John has been one of HRC's strongest supporters since taking over ownership of the Mariners in 2016.



Mike Milken and his grandchildren join Dodgers owner, Todd Boehly and his family to celebrate Father's Day and the conclusion of the HRC Tour at Dodger Stadium.



The Shenkman family have supported the Home Run Challenge for years. They joined Mike on-field at Yankee Stadium to cheer on their hometown team.

for the 2018 Home Run Challenge!



After witnessing the profound effect the Home Run Challenge had, MLB expanded the campaign from 1 week to the entire 3 weeks leading up to Father's Day. Thanks to this expansion, MLB players hit 530 home runs during the campaign, which resulted in \$2.4 million raised through pledges and donations! HRC continues to prove its efficacy in fighting for men and families battling prostate cancer worldwide.



Longtime HRC supporter, Bob Barth is joined by Dodgers legend Tommy Lasorda on the field at Dodger Stadium on Father's Day.



Mike joins Milwaukee Brewers owner, Mark Attanasio (left) and Wisconsin's Kohler Company chairman, Herb Kohler (center) at Miller Park for one of the best games of the HRC Tour.

Never Give Up: The Journey from Metastatic to Complete Response

Stephen Eisenmann saw his metastatic diagnosis as a problem to be solved... and PCF-funded doctors and researchers helped him do it.

Stephen met his wife Elizabeth in 1990 when they were both working together. There was an instant spark, but they didn't think much of it at the time since they were both married to other people. Much later, after they had both divorced, Elizabeth moved to Switzerland. "He found me when I moved back to the United States," says Elizabeth. "This friend of mine calls and says, OK, Steve Eisenmann is going to call you and ask you out on a date; he is so bad at this that you are not going to know that he is asking you out on a date... and you're so bad at it that you are not going to realize what's happening. So I'm telling you."

If you're the kind of guy who is willing to wait 12 years for a woman, I think it's safe to say you're the kind of guy who refuses to give up easily.

So, when Stephen was diagnosed with metastatic prostate cancer in 2016, there was no way he was going down without a fight; "I determined this was a problem to be solved. And at that point, I kind of sat back and I said, 'Hmm. What's the first step?'" Stephen used every resource at his disposal, called on friends, and made connections. Eventually, he ended up speaking with PCF CEO Jonathan Simons who recommended he meet with PCF-funded researcher and medical oncologist Dr. Dana Rathkopf at Memorial Sloan Kettering Cancer Center.

Dr. Rathkopf put Stephen on the standard of care at the time - continuous hormone therapy combined with chemotherapy for 6 treatment cycles. Stephen responded to the treatment, and his PSA went down to undetectable. Nevertheless, after about a year, Dr. Rathkopf decided to perform repeat imaging to confirm the response. Despite an undetectable PSA blood test, the imaging showed enlarging lymph nodes. The prostate cancer was back, even though Stephen wasn't making any PSA. "I said, 'No big deal,'" recalls Stephen. "We'll just go to the next drug."

Unfortunately, it wasn't that simple. Dr. Rathkopf explained that most current treatments and clinical trials assume that the patient's cancer cells are making some PSA. Approximately 5% of prostate cancer patients don't make any PSA, and Stephen was one of them. "There are few trials for men in your situation who don't make any PSA."

"When you meet the love of your life so late in life - the whole thing is just like this gut punch," says Elizabeth, "it was just devastating." But Dr. Rathkopf, never one to give up either, clarified that while there were few treatment protocols for his cancer, there might be a precision drug. She biopsied his cancer to figure out if there were any genomic markers they could use.



Meanwhile, just days before Stephen's test results came back, a PCF-funded study out of the University of Michigan found that about 6.9% of prostate cancer patients had a mutation in a gene named CDK12, and that some of those patients had responded to pembrolizumab, an immunotherapy drug that was approved for the treatment of other cancers, but not prostate cancer.

Then the best of the worst of news came in: Stephen had a CDK12 gene mutation marker.

Dr. Rathkopf wanted to give the pembrolizumab immunotherapy a try, but she also wanted Stephen to get a second opinion to ensure that "no stone was left unturned". She sent him down to Johns Hopkins to see another PCF-funded investigator and medical oncologist, Dr. Emmanuel Antonarakis.

Stephen's wife was unrelenting in her questioning of Dr. Antonarakis.

Elizabeth asked if all Stephen's cancer cells made CDK12. Dr. Antonarakis said they did. Elizabeth asked if pembrolizumab killed all cells that made CDK12. Dr. Antonarakis said that it did.

"So, are you telling me he could be cured?" Elizabeth asked. "We don't use the word cure, we prefer the term complete remission," said Dr. Antonarakis.

Elizabeth looked at Stephen and said, "Okay honey, we're going out to celebrate. We got this. You're going to be cured. I know, it sounds crazy."

Since all of the patients in the CDK12 Michigan study had prostate cancer that made PSA, the exact treatment protocol for Stephen was not set in stone. He was basically an "N of 1," as doctors like to say, or his very own clinical trial of one person. They agreed to give Stephen 4 cycles of pembrolizumab, then retest.

But between cycles 2 and 3, Stephen began to feel that his urination had changed. Dr. Rathkopf decided to order another imaging study to evaluate this change, since PSA was not a reliable measure in this case. Stephen was already on his way to his fourth and final treatment the day he missed a call from Memorial Sloan Kettering about his test results.

When Stephen arrived at MSK within the hour, Dr. Rathkopf brought in her whole staff to tell him the news. After only 3 cycles of pembrolizumab, results of his imaging showed a complete response to the treatment.

"The Prostate Cancer Foundation saved my life," says Stephen, "Dr. Rathkopf saved my life. My wife and my family saved my life. I'm the beneficiary of all that, and I'm the luckiest person in the world."




Dana Rathkopf, MD, at Memorial Sloan Kettering Cancer Center in New York, is a PCF-funded medical oncologist who treated Stephen Eisenmann.

Dr. Rathkopf is a 2011 PCF Young Investigator and a 2016 Movember Foundation-PCF Challenge Award Co-Investigator.

Stephen continues to receive pembrolizumab treatments every 3 weeks to keep his prostate cancer at bay. But he doesn't mind. "I never looked at this like being defeated. My grandkids are a big motivating factor, you know? I want to be there when they get married," says Stephen. "My father taught me: Never give up. Always fight. Always find a solution."

How PCF Research and Real-Time Collaboration Saves Men's Lives



2015


Responding to **PCF-FR*** (and now Nobel Prize winner) James Allison's data on checkpoint immune drugs, PCF funds a study at Univ. of Michigan by Dr. Arul Chinnaiyan to **explore using genomics in prostate cancer.**

Chinnaiyan & Rahr Foundation-PCF team publish their results in *Cell*, **categorizing gene mutations in prostate cancer**, among them the CDK12 gene mutation.



MAY

2015



JUNE

2016


Eisenmann is diagnosed with metastatic prostate cancer, despite the fact that he's making no PSA. His treating physician, **PCF YI*** Dr. Dana Rathkopf at MSKCC has Eisenmann genetically tested. **He has the CDK12 mutation.**

PCF-FR Dr. Julie Graff at OHSU applies the result of Chinnaiyan's work in a small pilot study and begins to see **exceptional response for those with CDK12 treated with pembrolizumab.**



JULY

2016



JULY

2016

Although the specifics of Eisenmann's situation don't 100% match (because he makes no PSA), **Rathkopf sees an opportunity to use PCF unpublished data to treat him with pembrolizumab**, since he carries the CDK12 mutation.

Since this is uncharted territory, Rathkopf sends Eisenmann to Johns Hopkins Univ. to meet with **PCF YI** Dr. Emmanuel Antonarakis for a second opinion. **Eisenmann starts on pembrolizumab.** The initial plan calls for 4 doses of the drug.



JULY

2016



SEPT

2016

Three treatments into the protocol, Eisenmann's scans show that he is having a complete response to treatment. **The tumors in his lymph nodes had melted away.**

PCF YI Dr. Wassim Abida at MSKCC then studies Eisenmann, **applies what he learns to patients with other mutations**, and publishes in *JAMA Oncology*.



MARCH

2019

***PCF-FR** = PCF-Funded Researcher
PCF-YI = PCF Young Investigator

Supporting Cures

There are millions of men currently living with prostate cancer. To support the urgent need for better treatments and cures, the Prostate Cancer Foundation offers individuals and charitable foundations various options for becoming involved and supporting crucial research.

Donations

Please mail your check to:

Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, CA 90401

To make an online contribution, please visit our website
www.pcf.org

Blue Ribbon Society

- ▶ Join our elite group of loyal supporters devoted to fostering breakthrough science with a monthly recurring contribution

Memorial or Tribute Gifts

- ▶ Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others with a tribute gift
- ▶ If desired, PCF can also set up a special webpage to honor your loved one and collect donations

Matching Gifts


- ▶ If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far with a matching gift to PCF

Other Gift Suggestions

- ▶ Gifts of stock
- ▶ Support PCF in your estate planning
- ▶ Name PCF as a beneficiary of your IRA or life insurance policy
- ▶ Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary

For more information, visit:

www.pcf.org/donate



PCF Research Awards

PCF advances its research priorities through 3 competitive award types:

Challenge Awards

(\$1,000,000 and above for 2- to 4-year programs)

Challenge Awards make large investments in multi-year team science projects that have a high potential for delivering new treatments.

Creativity Awards

(\$300,000 for 2-year programs)

Creativity Awards support the development of high-risk, high-reward ideas from established senior scientists.

Young Investigator Awards

(\$225,000 for 3-year career investment)

The Young Investigator Awards offer early-career and project support for the ideas of exceptional investigators (generally 35 years old and younger), who are committing their lives to the field of prostate cancer. Their institutions match the award dollar-for-dollar.

PCF-VA Center of Excellence Awards

In 2016, the PCF committed to invest \$50 million over five years to advance precision medicine for America's veterans. Together, PCF and the U.S. Veterans Administration are building a network of Precision Oncology Centers of Excellence focused on expanding access to genomic sequencing and innovative clinical research.

2018 Donor Roll

The support of our generous donors makes all that we do at PCF possible. This honor roll acknowledges actual gifts of \$1,000 or more, exclusive of pledges, made to PCF during calendar year 2018. We thank you, our friends and supporters, for your continued commitment to PCF's mission.

\$1,000,000-\$4,999,999

Mr. John Barry and Mrs. Daria Becker
Bernstein Equity Partners LLC
Blavatnik Family Foundation
Stein Erik Hagen Allmenyttige
Stiftelse
Milken Family Foundation
Movember Foundation
The Stewart J. Rahr Foundation

\$500,000-\$999,999

AJA Charitable Fund
The John Black Charitable Foundation
Todd Boehly
Mr. Izzy Englander
Janssen Research and Development,
LLC
Kern Family Fund
The San Francisco Foundation
The Stupski Foundation
Teach A Man To Fish Foundation

\$250,000-\$499,999

Anonymous [2]
Drew Foundation
Edward P. Evans Foundation
Facebook, Inc.
The Foundation of Man, LTD
Genzyme, Inc.
Peter and Laurie Grauer
Independence Blue Cross
David G. Kabiller
Mr. Morris Kahn
The Morris and Alma Schapiro Fund
Trailsend Foundation
The V Foundation for Cancer Research

\$150,000-\$249,999

Reina and Emilio Bassini
Clovis Oncology, Inc.
The Durden Foundation, Inc. / Mr.
Michael Durden / Mrs. Earl Durden
The Eustace Foundation Trust
Clay and Lynn Hamlin
The Katz Family Foundation - Drew
Katz
Howard and Nancy Marks
Flora and Morris Mizel Foundation II
Nicklas Family Foundation
Estate of Calvin Patterson
Mr. Arthur Rabin
Ms. Georgina Rinehart
Mr. and Mrs. Roger Taylor
WorldQuant Foundation

\$100,000-\$149,999

Joseph and Annette Allen
Amgen, Inc.
Bayer HealthCare Pharmaceuticals,
Inc.
Dr. Michael M. Berns and Tricia Berns
The Bill and Ann Bresnan Foundation,
Inc.
Robert & Cynthia Citrone
Mr. Michael DeAddio
Eldridge Business Services, LLC
Mr. Joel Farkas
Louis and Beth Graziadio
Mr. Kenneth C. Griffin
i-Future Teens International
Foundation
Mr. and Mrs. Steven B. Klinsky
Dalia & Larry Leeds/The Leeds Family
Foundation
Major League Baseball Charities, Inc.
Modell's Inc.
Ms. Catherine Moraetis
Paulson Family Foundation
Pfizer, Inc.
The Ressler Family Foundation
Ms. Alice Rogoff and Mr. David M.
Rubenstein
Mr. Nicholas S. Schorsch
Mark and Rosalind Shenkman
Mr. Thomas S. Smith and Ms. Caroline
Fitzgibbons
Jeffrey Tarr, Sr.
Ted and Dani Virtue
Weisscom Partners Inc.
Zisk Family Foundation

\$50,000-\$99,999

1 RFP Limited Partnership
Anonymous [2]
Astellas, LLC
Mark and Debbie Attanasio
Ron and Judy Baron
Douglas and Joanne Berry Charitable
Fund
Bristol-Myers Squibb Company
Arthur and Eva Byrnes
Casamigos Tequila LLC
Ray and Patti Chambers
Coller Capital
Dendreon Corporation
Dendreon Pharmaceuticals
DMC Holdings Limited
The Christian Thomas Doerr
Donnini-Rudolph Family Foundation
Eugene and Sallyann Fama
Mr. Michael Ferro

Mr. Michael W. Ferro, Jr.
John R. and Kiendl Dauphinot Gordon
Fund
Jefferies & Company, Inc.
Jordan Industries, Inc.
William P. and Dorian S. Jordan/
William P. and Dorian S. Jordan
Foundation, Inc.
Kissick Family Foundation
The Laughlin Aldisert Family Fund
Thomas H. Lee and Ann Tenenbaum
The Maguire Foundation
The Milana Family Foundation, Inc
R.N. Milikowsky Family Foundation
Minnesota Twins
Mr. Thomas P. Nerney
Progenics Pharmaceuticals, Inc.
Republic National Distributing
Company, LLC
Michael J. Rinaldi Jr. Revocable Trust
Cliff and Debbie Robbins and The
Robbins Family Foundation
Marc J. and Carolyn Rowan
Satter Foundation
Mr. Ilan Shalit
Mr. Brian Sheth
Ms. Lucy Shostak
Mr. Scott Simon and Mrs. Hillary
Simon
David E. and Jacqueline S. Simon
Charitable Foundation
Mr. Frederick Smith and Mrs. Cheryl L.
Smith
Sun Pharmaceuticals Industries
Ms. Roxann Taylor
The Thompson Family Foundation
The Robert & Jane Toll Foundation
The Wagner Family Foundation/
GoldenTree Asset Management
Nancy & George Walker Foundation
Mr. Andrew S. Weinberg
Mark & Nancy Weinberger Family
Foundation
The Weintraub Family Foundation
Wild Dunes Men's Golf Association
Yurman Family Foundation, Inc.

\$25,000-\$49,999

Dr. Elliot Abramowitz
Mr. and Mrs. William A. Ackman
Mr. Dwight Anderson
Anonymous [4]
Astellas Pharma Global Development,
Inc.
Mr. Duncan Bagshaw and Mrs. Lisa
Bagshaw
The Barth Family Foundation

The Cecile & Fred Bartman Foundation
Candice Beaumont
Sybiel B. Berkman Foundation
Mr. Benjamin E. Black
Anthony and Jamie Carr
Mr. Anthony Carr
Johnny Carson Foundation
Mr. John Cefaly
Ms. Jolene S. Cherry
Chicago White Sox
Clark.com
Jerry and Adrienne Cohen
Mr. Robert D. Collins
Howard Cox
Mr. and Mrs. Eric K. Davidson
Neil and Sandra DeFeo Family
Foundation
Derric's Day for Prostate Cancer
Awareness
Leo and Marcy Edelstein
Mark and Sally Ein Foundation
Bethany and Niko Elmaleh
Endocyte, Inc.
Faith, Love, Hope, Win Foundation
Seymour Feldman Foundation, Inc.
Mr. and Mrs. Sidney Ferenc
Mr. Jim Filler and Mrs. Carol Filler
Ralph and Cynthia Finerman
The Stella Hall & James Fordyce
Foundation
Mr. Emanuel J. Friedman
Genentech, Inc.
German Masonic Charitable
Foundation
Mr. Gerald Gibian
Goldman, Sachs & Co.
John A. Griffin
Griffon Corporation
Nancy and Joel Hart Charitable
Foundation
Sam Herzberg
Immunomedics Incorporated
Indigo Auto Group
Mr. John F. Klein and Mrs. Jennifer A.
Klein
Ms. Elizabeth Kojima
Ms. Jane Lauder
Leonard and Evelyn Lauder
Monica Lester Charitable Trust
Marc & Jennifer Lipschultz Family
Foundation
Mr. Robert J. Lothenbach
Mr. Howard Lutnick and Mrs. Allison
Lutnick
John & Linda MacDonald Foundation
Medical Research Charities
Jerome Meislin
Mr. Michael A. Mendelson

Dorothy Phillips Michaud Charitable Trust
 Mr. Christian L. Oberbeck and Mrs. Katia Oberbeck
 Mr. Robert L. Pike, Jr.
 Ms. Robyn Rabin
 Rance King Properties, Inc
 Redbird Capital Partners
 Resilience Management, LLC.
 Ronald Rubin
 Mr. Arik Ruchim
 Sanofi-Aventis
 Sempermed USA, Inc.
 Mr. Mickey Shapiro
 Shostak Charitable Trust
 Mr. Ron Sussman
 Mr. Steven Tananbaum and Mrs. Lisa Tananbaum
 Julie and Bobby Taubman
 Tyson Family Foundation
 Mr. Vincent L. Verdiramo
 Ted and Dani Virtue
 The WAF Trust
 Mr. George H. Walker and Mrs. Nancy Walker
 Estate of Jerry Wasserman
 Mrs. Cindy Wolfe

\$15,000-\$24,999

Mr. Duane Andrews and Mrs. Rebecca Andrews
 AstraZeneca
 The Elias, Genevieve and Georgina Atol Charitable Trust
 Mr. Richard Baker
 Roger Barnett
 Bellavia Blatt, P.C.
 Mr. and Mrs. Seth Bernstein
 Mr. Edwin Charles Bessant
 Mr. David Blado
 Ms. Maureen D. Casey
 Constellation Pharmaceuticals
 Credit Suisse Securities (USA) LLC
 Mr. Michael A. DeMayo
 David and Marsha Ederer
 Jack Farrell
 Dan Fellman
 David and Judith Fleischer
 Ryan Freedman, Corigin Holdings
 Gateway American Resources, LLC
 Bennett and Meg Goodman
 Jim Gordon, The Edgewater Funds
 Harpoon Therapeutics
 Mr. Lawrence H. Hayward and Mrs. Sheree Hayward
 Hologic Gen-Probe
 Hope Motorcycle Rally
 Mr. Steve Hytner
 Mr. Arik Kislun
 Mr. Edwin L. Knetzger, III
 Lateral Investment Management, LLC
 Alice Lawrence Foundation, Inc.
 Mr. Edmund Lomasney
 Mr. Chester C. Lucido, Jr.
 Maple & Corona, Inc.
 Mr. and Mrs. Michael Marquart
 Donald B Marron Charitable Trust

Mr. John Meglen
 Merck Polaris
 Merkin Family Foundation, founded by Richard Merkin, M.D.
 Mr. C. Dean Metropoulos
 Mr. and Mrs. Henry L. Nordhoff
 The Olde Course at Loveland - Prostate Cancer Invitational
 Mr. Steve Papazian
 Mr. Gerald L. Parsky
 Ms. Julie Picache
 Sandra and Lawrence Post Family Foundation
 Reiter Affiliated Companies, LLC
 Harold W. Ripps
 Mr. Bruce Rosenblum
 Mr. David A. Sachs and Mrs. Karen Richards Sachs
 Jason Safriet
 San Diego Golf Course
 Superintendents Association
 Ellen and Richard V. Sandler/Richard and Ellen Sandler Family Foundation
 Kern Schumacher Family Trust
 Richard and Phyllis Sharlin
 Mark J. Simon
 Mr. Thomas Smith
 Ms. April Marie Smith
 Mr. Howard Smith
 St. Andrews Foundation
 David A. Steinberg Family Foundation
 Sunny Frog Investments, LLC
 Mr. Vincent Taormina
 Douglas P. Teitelbaum
 Mr. Robert L. Thornton, Jr.
 Alexander J. Witherill
 George D. Yancopoulos, M.D., Ph.D.
 Mrs. Hsin Yue Yong
 Barbara and David Zalaznick Foundation

\$10,000-\$14,999

A Charity Challenge at Broken Sound Club
 Joseph P. Adams, Jr.
 Anonymous
 Eric Aroesty
 Mr. Jeff Assaf and Mrs. Cecelia Assaf
 Mr. Joe Banfield
 Mr. Jon E. Barfield
 BB&T Corporation
 Beneficial Bank
 Dr. Laurence Blumberg, M. D.
 Mr. and Mrs. David C. Brown, Jr.
 Courtney and David Corleto
 Mr. and Mrs. William Curry
 D.E., Inc
 P & M Dipaola Family Foundation
 EJF Philanthropies
 R.S. Evans Foundation
 Galman Family Trust
 William D. Gulick Marital Trust
 Drs. Kerry Hagen and Kelly Chung
 Ms. Shirley Johnson
 Stephanie and Ron Kramer
 Dr. Suzanne Levine
 Dr. Edward Loftspring

The Honorable Earle I. and Carol Mack
 The Bill and Jodie Mackintosh Family
 Mr. Marlin McKeever
 Mr. and Mrs. George A. Mealey
 Shmuel Meitar
 Mr. Eliot N. Meyers
 Mark and Lisa Neporent Family Foundation
 Paramus PBA Local 186
 Mr. Evan Sacks
 Mr. Sandro Salsano
 The San Diego Foundation
 Mr. Michael H. Scott
 Sheffield Pharmaceuticals
 Silvercrest Asset Management Group, LLC.
 Skelton Family Fund
 Mr. Justin W. Slatky
 Mr. William Smith
 Mr. Michael S. Smith and Mrs. Elizabeth A. Smith
 Will K. Weinstein
 Terry L. Wright
 Mr. Mark S. Zucker

\$5,000-\$9,999

AmeriGas Propane
 Anonymous [4]
 Battle at Bella Vista
 Mr. Barak Berkowitz and Ms. Kaori Kuroki
 Mr. Keith Bertolino
 Mr. Todd L. Blue
 Bonanza Casino
 C.A.R.E.
 Dr. Eric Campeau
 Castellini Foundation
 CF Global Trading, LLC
 Mr. Howard Chai
 Mr. Marvin Chanin and Mrs. Dottie Chanin
 Gary Charlesworth
 Cherotti Enterprises, Inc.
 Mr. David R. Chubon
 Cincinnati Reds
 Mr. Mitchell Clarfield
 Ms. Ramola Daswani
 Digital Science Press, Inc.
 Stephen Edelmann, Edelmann Family Foundation
 Elizabeth Ventura and Stephen Eisenmann
 Mr. Peter Fisher
 Four Peaks Brewing Co.
 FragranceNet
 Fuego Box LLC
 Mr. Simon Furie and Mrs. Lori Furie
 Hartford Foundation for Public Giving
 Mr. Mark S. Henderson
 Douglas J. Hertz Family Foundation
 IBM Employee Services Center
 Ms. Julie C. Jaeger
 Ms. Ellie Kanner
 The Rachel & Drew Katz Foundation, Inc.
 Kelsey Family Charitable Fund
 Mr. Sven Kjaersgaard

Stacey and Larry Kohl
 Herb and Natalie Kohler
 Lowell D Kraff & Marc Byron - Trivergance LLC
 Mr. Philip Larman
 The Thalia & George Liberatos Foundation
 Douglas R. Lowe
 Mr. and Mrs. Eric Luse
 Mr. and Mrs. Paul Madura
 Mr. Robert Matloff and Mrs. Joan Lee Matloff
 F. W. McCarthy Foundation
 Mr. William McDaniel
 Meadow Club
 Memorial Sloan Kettering Cancer Center
 Ian Miller
 Dr. and Mrs. R. Bruce Montgomery
 Jay Moody Memorial Fund
 Mr. John G. Morris
 Ms. Jennifer Newman
 L. Mark Newman Family Foundation
 Mr. Mark Nicol
 Mrs. Robin Nordhoff
 Mr. Victor Pais
 Mr. Stephen Paluszek and Mrs. Violeta Paluszek
 Paluszek Family Foundation Inc.
 Mr. Bradford Peck
 Mr. Christian Poehlein
 Mr. Daniel Polett and Mrs. Margo Polett
 Pros4Care
 Mr. Douglas Rachlin
 RCM Rise & Shine Memorial
 Mr. and Mrs. Jay K. Rosenblatt
 Mr. Barry Schlesinger
 Mr. Richard L. Schmidt and Mrs. Dorothy A. Schmidt
 William and Valerie Schwartz Family Foundation
 Mr. Brian Selmo and Mrs. Suzanne Selmo
 Mrs. Suzy Shechtman
 The Shumway Foundation
 Simon Says Run for Prostate Cancer
 The Sloan Foundation
 Smithburg Family Foundation
 Mr. Carl Sperber
 Sweetwater Community, Inc.
 Mr. Richard J. Tarlow
 Mr. Stephen Tendrich
 Terravita Golf Club
 The Tuchman Family Foundation
 Mr. and Mrs. Michael W. Urbut
 Valiance Partners, Inc.
 Bradley Walsh
 Ms. Sharon Woolman
 The Yablon Family Foundation

\$2,500-\$4,999

Anglers for the Cure
 Advanced Technology Group
 Mr. Leland Alpert
 American Past Time Sports
 Anonymous [3]

Armonk Bobcat Baseball, Inc.
 C. R. Bard Foundation
 Mr. Gerard Barron
 Mr. Mark Bass
 Dr. Judy Bastedo
 Mitchell C. Benson, M.D.
 Mr. Thomas Biermann
 Mr. Antony Blinken
 BorgWarner Foundation
 The Boucher Charitable Foundation
 Mr. Steve Brauer
 Nigel Brooks
 Mr. Michael Bucella
 Mr. Jeffrey Burget
 Cancer Research Institute
 Mr. and Mrs. Richard Chadakoff
 Charles Maxfield Parrish and Gloria F. Parrish Foundation
 Isan Chen, M.D.
 Lucy Chen
 Allen and Jill Chozen
 Clarity Organization, Inc.
 Mr. Robert K. Cohen
 Mr. William Connolly
 Mr. James A. Davidson
 Mr. Ken Denison
 Mr. Bret D'Vincent
 Mr. Daniel M. Elperin
 Don Engel
 Mr. George C. Exarhacos
 Falcon Trading Company, Inc
 Ms. Ilya Feldman
 Mr. Thomas M. Finke and Mrs. Heather Finke
 Fleetcor Tech Operating Co LLC
 Fulcrum 2020, LLC
 Mr. Robert G. Fuller
 The Gibson Family Foundation
 Mr. and Mrs. Wayne Giebler
 Granite Construction Inc.
 Mr. and Mrs. Richard Granville
 Mr. William Greene
 Mr. Kent Gushner and Mrs. Mindy Gushner
 Thomas R. Hagadone and Pamela J. Miller
 Mr. Christopher Harrison
 Mr. Jason L. Hartley
 Estate of Alvin L. Hayes
 Ms. Barbara Jean Helvie
 Steven Higger
 The Hill Family Charitable Foundation
 Mr. Gregg Hine
 The Hwang Foundation
 IEC - Fort Worth Tarrant County Chapter/ IEC - Dallas Chapter
 IRA Services Trust Company
 Kenneth Iwata
 Mr. Tim G. Jaeger
 Mr. and Mrs. Tab E. Johnson
 Vijay Kasturi
 Kearney & Company
 Mark Landers
 Mr. William Lee
 Mr. and Mrs. Richard H. Lester
 Dr. Stephen H. Levine
 Dr. Karen E. Linder
 Lords Valley Country Club

Helena Mancebo
 Stewart Manheim
 Mr. and Mrs. Robert Mansfield
 Mr. Thomas J. Maresh and Mrs. Carolyn R. Maresh
 H. Gordon Martin Foundation
 Ms. Rebecca Mieczkowski
 Mr. Paul J. Milbury
 Ms. Marcia Moore
 Dr. Taavi Neklesa
 Network360
 James W. Newman
 Mr. and Mrs. Scott G. Nichols
 Mr. Xiaopeng Niu
 Jonathan R. Novak
 John Paffenbarger
 Palm-Aire Country Club at Sarasota
 Mr. George M. Pehanick and Mrs. Gretchen Z. Pehanick
 Ms. Kathy Pickl
 Mr. and Mrs. James T. Pizzo
 Poseida Therapeutics
 Prior Lake - Savage Area Schools
 Mr. Jonathan Ressler
 James S. Riepe Family Foundation
 Mrs. Louise C. Rigg
 Mr. Michael J. Roach
 Drs. W Scott and Karen T Robertson
 Edward B. Rust, Jr.
 Mr. David Schreiner
 Ms. Stacy Carter and Mr. Benjamin Shabtai
 Mr. Gary Singer
 The Sire Foundation
 Erik Smith
 Ms. Adriana Somberg
 Mr. E. Per Sorensen
 Mr. Joseph E. Kane and Ms. Carol M. Stamps
 Roger and Susan Stone Family Foundation
 Sun Home Services, Inc.
 David V.N. Taylor Foundation
 Mr. Eric Thomassia
 Mr. E. Paul Tinsley
 The Tom Fund
 Mr. Donald J. Toumey
 Ms. Trish Turrin
 University Park Country Club Associates
 Wim van Schooten
 Mr. James Vanlandingham
 Ms. Caroline A. Walker
 Walker Chrysler Dodge Jeep Ram
 Mr. Alwin J. Wenzel
 Mr. Theodore Woehrl and Mrs. Pamela Woehrl
 Ms. Rebecca Rose Woodland
 ZV NY, Inc.

\$1,000-\$2,499

4th Annual Santa Cruz Stache Dash
 Alden and Elizabeth (Bette) Abraham
 Charitable Gift Fund
 Mr. Tom Adkin
 Stan Adler
 Mr. and Mrs. David C. Allen

Alta Data Technologies, LLC
 Mr. Richard W. Alvord
 Mr. Joe Alwan and Mrs. Mary Ann Alwan
 Mr. Denis J. Amato and Mrs. Janice Amato
 The Amaturio Family Foundation, Inc.
 AmazonSmile Foundation
 Mr. Jim Anderson
 Anonymous [13]
 Mr. Gerald W. Apel and Mrs. Kathleen Apel
 Mr. Alan Appelbaum
 Arc International North America
 Mr. Eliot Arnovitz and Mrs. Phyllis Arnovitz
 Aviation Spectrum Resources, Inc. (ASRI)
 AZ State Rifle and Pistol Association - Shotgun Division Blue Ribbon Clays Tournament
 Mr. Moshe Azogui
 Jeffrey and Pamela Balton
 Paul Baranay
 Mr. Thomas E. Beach
 Beaver Valley H.O.G.
 Fred Bedard
 Mr. and Mrs. Richard Beebe
 Mr. Joseph Bellemore
 Mr. and Mrs. Barry M. Berish
 Mr. and Mrs. Saul G. Berkowitz
 Mr. and Mrs. Barry Berlin
 Mr. John Bermel
 Mr. Donald B. Berz and Mrs. Janine Berz
 BGC Legs
 Mr. and Mrs. Fred B. Bialek
 Mr. William Biebusch and Mrs. Doreen Biebusch
 Mr. Jack Binion
 Mr. Robert Blum
 Bernt O. Bodal
 Ms. Christine Bogharian
 Mr. Richard Bogomolny and Ms. Patricia Kozerefski
 Mr. Richard Boland and Mrs. Colleen Boland
 Dr. and Mrs. Carl W. Bollwinkel
 Ms. Heidi Borowiecki
 Mr. Bruce Botchman
 Mr. Stephen Bowen
 Mr. and Mrs. Todd J. Brading
 Braman & Associates, Inc.
 Mr. Peter E. Braveman
 Mr. Eric Braverman
 Mr. Michael Bray and Mrs. Barbara Bray
 Mr. James Breen
 Mr. Dermot Brennan
 Mr. Emil J. Britt, Jr.
 Ms. Karen Broadnax
 Mr. Mark Brooks
 Mr. Jono Brown
 Mr. Walter W. Brown
 Mr. and Mrs. Douglas Brown
 Mrs. Deb Brown
 Mr. Samuel Brown
 David P. and Jerilyn Brownell
 Mr. Duane Buehner

Mr. David Bunevich
 Craig and Caryn Caffarelli
 Mr. Ross Cahn
 Mr. Robert Campbell
 Carolina Trace Men's Golf Association
 Mr. Richard E. Carroll and Mrs. Susan G. Carroll
 Mr. Clay Cassel
 Castaways Foundation
 Mr. Michael Castellano
 Castro Village, Inc.
 Centennial School District
 Mr. Al Ceresa
 Mr. James Chao
 Mr. Mark M. Chatfield
 Mr. C. J. Cherre
 David and Suzanne Chonette
 Mr. Caspar Chou
 Mr. Michael Ciaccia
 Ms. Emilia Clarke
 Mr. and Mrs. James T. Clarke
 Mr. Steve Clough
 CNE Direct
 Ms. Christine Cole
 Ms. Jennifer R. Cole
 Mr. and Mrs. Kurt A. Conti
 Mr. Clay Cook
 Mrs. Tisha Cornwall
 Stephen W. Craig Family Foundation
 Mr. Bill Crook
 Mr. and Mrs. James L. Crothers
 Mrs. Doris Crouch
 CT Spa Group, LLC
 Mr. Laurence Cusick
 Mr. Alec Dafferner and Mrs. Elizabeth Dafferner
 Mr. Joseph L. D'Amico
 Mr. Ross Dargahi
 Mr. Carlton Davis
 Mr. Jack Devaney
 Mr. Barry Didato
 Mr. A.W. Dieffenbach, Jr.
 Joseph DiNapoli, Sr. Memorial Golf Outing
 Mr. and Mrs. E. James Dixon
 Mr. Steven L. Dobbstein
 Mr. Gilbert Dodson
 Mrs. Julie Dodson Baisinger
 DonateWell
 Mr. Don Douglas and Mrs. Carolyne Douglas
 Mr. Laurence Downes
 Mr. and Mrs. Joseph D. Doyle
 Mr. and Mrs. William E. Dreyer
 Ms. Tina Driscoll
 Mr. Michael Duff and Mrs. Meg Duff
 Mr. Matthew Dunham
 Michael Dunitz Crisis Foundation
 Mr. James Dunn
 Mr. and Mrs. Robert J. Dunne III
 Mr. Peter J. Durfee
 Eagle Group
 Mr. and Mrs. James W. Eggenberger
 Mr. James Eide
 Einhorn Family Charitable Trust
 Mrs. Elizabeth Eisenmann
 El Conquistador Country Club Men's Golf Association

Mr. Albert L. Engel and Mrs. Jane M. Engel
Ms. Jenica Erickson
Mr. Dennis Esposito
Edward P. Evans Foundation
Mr. Robert G. Fair
Ms. Bayla K. Falber
Mr. Eric Falkenberg
Mr. and Mrs. Steven J. Farella
Mr. & Mrs. Michael Farrell
Dr. and Mrs. Clyde Farris
Mr. Edward J. Felten
Ken and Caryl Field
Mr. Jerome Fiore and Mrs. Terri Curtis
Ms. Sandra Fitzgerald
Mr. Alan Fodor
Ms. Marian R. Foldberg
Mr. Jack Foxworth
Larson Freitag Charitable Giving
Mrs. Deborah Freund
The Philip M. Friedmann Family Charitable Trust
Dr. and Mrs. Mark H. Fritze
Mr. and Mrs. William Frumkin
Fuccillo Affiliates of Florida - Fuccillo Kia of Cape Coral
Mr. William C. Fuller, Jr.
Mr. Charlie Gable
Ira S and Anna Galkin Charitable Trust
Mr. and Mrs. J. Donald Garvey
Mr. and Mrs. Donald A. Gill
Mr. James Gizzonio
Mr. Raj Gohill
Ms. Suzanne Gold
Ms. Jennifer Goldman
Mr. and Mrs. Jonathan P. Goulding
Ms. Marianne Grady
Mr. William Gregory
Reverend Roosevelt Grier
The Sam and Sarah Grossinger Foundation
Mr. Jay Grossman
Mr. Vishal Grover
Dr. Ralph F. Guertin
Mr. Theodore Haard
Mr. Richard Haddrill
Mr. and Mrs. Donnie C. Haggard, IV
Mrs. Barbara Haines
Ms. Julie A. Hansen
Mr. Robert Hart
Ms. Jennifer J. Hartland
The Maurice Hatter Foundation
Mr. and Mrs. John Hazen
HDR
Mr. and Mrs. William H. Healy, Jr.
Mr. Mark Henderson
Ms. Stephanie Hensel
Heron's Glen Men's Golf Association
Mr. Andrew Herz and Mrs. Phyllis Herz
Mr. Daniel Hewitt
Ms. Leah Hindy
Mr. Don Hirth
Mr. John W. Hoffee
Mr. Herbert D. Hollinger and Mrs. Ruth A. Hollinger
Mr. William E. Honey
Mr. Anthony Hook
Mr. and Mrs. Larry Horn

Ms. Aviva Carmy and Mr. Harry Horowitz
William B. Hotaling
Mr. and Mrs. Jack Hudspeth
Mr. Norman Hurt and Mrs. Susan Hurt
Mr. and Mrs. Raymond Hwang
Steve Iverson
The Jacobs Institute and the State University of New York Buffalo
Mr. and Mrs. Daryl L. Jespersion
Mr. and Mrs. John Jester
Mr. and Mrs. Richard A. Johnson
Mr. Kenneth Jones
Lt. Col. Gary Jones and Mrs. Christine Jones
Judd Apatow
Mr. Arnie Jungkind
Mr. and Mrs. Stuart Kalman
Mr. Thomas G. Kamasky and Mrs. Ann L. Kamasky
Dr. Lewis Kanengiser and Mrs. Sandra Kanengiser
Mr. and Mrs. Michael Kaplan
Mr. Ira Katz
Ms. Mary Kaufman
Mr. Joseph A. Kiat and Mrs. Penny Kiat
Mr. Jonathan Kirschner
Mr. Christopher Kleiman
Mr. Lloyd Klein
James W. Klein
Arlene and Michael J. Klosk
Arlene and Michael J. Klosk
Knoxville Law Enforcement Federal Credit Union
Harold and Shirley Kobliner
Mr. Robert Kraft
Mr. Richard S. Kramer
Mr. and Mrs. Thomas R. Krull
KSB Dental
Mr. and Mrs. Frank Kulze
LA-CO Industries, Inc.
Lakeland Bank
Ms. Debbie Lanni
Mr. Brad Lanpher
Mr. Brent Larsen
Mr. and Mrs. Scott D. Larsen
Mr. Jeff Layne and Mrs. Stefanie Layne
Ms. Maria Leahy
Ms. Kay Ledyard
Dr. Daniel Lehman
Mr. and Mrs. Dennis Leuthauser
Mr. John A. Lever
Mr. George Levie
Mr. and Mrs. Robert Limburg
Mr. Gabriel Loh and Mrs. Susan Loh
Mr. and Mrs. Gerald A. Long
Chris and Krista Loose
Mr. and Mrs. Kenneth G. Lore
The Lore Family Fund
Charles Lowrey and Susan Rodriguez
Mr. and Mrs. Christopher Luetzow
Gordon Maahs
Mr. Duane J. Macqueen
Mr. Jacob Mandel
Mangen Family Charitable Foundation
Manowitz and Drillings Family Foundation
Marlborough Country Club, Inc.

Mr. Atwood R. McAndrew, Jr.
McCown Family Foundation
Mr. William McIntosh
The McKelvey-Daugherty Family Foundation
Mrs. Ann McKinney
Mr. Jeremy McKoon
Laureston and Barbara McLellan
Mr. and Mrs. Harry McMillan/McMillan and Associates
Mr. and Mrs. Donald A. McMullen, Jr.
Mr. Robert Mehm
Ms. Susan Melnicki
Menarini Silicon Biosystems, Inc.
Mr. Thomas Metzler
Mr. Ron Meyer
Mr. and Mrs. Jack Meyers
Middlesex County Sheriff's Office
Midwest Eye Institute
Mr. Robert J. Milhiser and Mrs. Carol J. Milhiser
Mr. and Mrs. James I. Miller
Ted and Donna Miller
Ms. Pamela R. Money
Ms. Natasha Moore
Bill Morgan
Linda and Michael Morgan
Cameron Moulene
Angelo and Phyllis Mozilo
Mr. and Mrs. Paul R. Murphy
Mr. and Mrs. Herbert Muther
Mrs. Kathleen Myers
Mr. and Mrs. Sal Nesto, Jr.
Blake Lee and Carolyn L. Neubauer
Neuberger Berman, LLC
Mr. Craig Newland
Carol and Reg Newman
Karen Preble Nichols
Mr. Bret Norton
Ms. Nancy Novak
Mr. Thomas L. Oakey
Dr. and Mrs. James E. O'Brien
Mr. and Mrs. Henry Ondrusek
One Capital Management, LLC
OTF Mohill Ownership Team
Ms. Tracy Owens
Mr. Phillip Patch
Mrs. Sureshrani Paintal
Mr. Michael Pansini
Ms. Judith A. Pantera
Mr. Samuel H. Paris
Mario and Alma Pastega Family Foundation
Mr. and Mrs. Toby Paterson
Steven R. Patierno, Ph.D.
Patio Ranch, LP
Thomas J. Patrician
Mr. Cartter Patten
Mrs. Jennifer Pazzia
Mrs. Gretchen Pehanick
Pelican Pointe Mens Golf Association
Daniel P. Petrylak, M.D.
Mr. Bernard L. Pfefer
Jennifer and Ken Phillips
Pi Lambda Phi Fraternity
Polaris Industries Inc.
Mr. and Mrs. Joe Porcelli
Mr. Allen Porter

Sandra and Lawrence Post Family Foundation
Mr. John Poth
Ms. and Mr. Mary Ann Powell
Gail S. Prins, Ph.D.
Ms. Gelila Puck
Mr. Wolfgang Puck
Mr. and Mrs. William Pullia Jr.
The Rabinowitz Foundation
Mr. and Mrs. John Raffetto
Muhit and Anna Rahman
Conner Ramos Family Giving Fund
The Rapaport Family
Mr. and Mrs. Warren Rasmussen
Ms. Melissa Rauch
Mr. John Rauth
Mr. Mark Redouley
Kathleen Redmond
Researchpoint Global
Mr. Gregory Richardson
The Donald Richter Trust
Mr. and Mrs. Harold E. Rickards
Mr. Donald E. Riesbeck
Major Charles N. Riley
River Dell Lacrosse Association
Mr. Tucker Robinson
Mr. and Mrs. Michael Rochester
Mr. Michael Rock
Mr. Michael T. Rollings and Mrs. Kathleen H. Rollings
Mr. Brian Rooder
Mr. Alfred Rose
Mr. Harvey Rose
Mr. Marc Rosen
Mr. Robert Rosenbaum
Dr. John Rosenbaum
Mr. Robert Rosenberg and Mrs. Jackie Rosenberg
Mr. Lawrence Rosenthal
Mr. and Mrs. Edward Ross
Mr. Jonathan P. Roth and Mrs. Alison G. Roth
Mr. James A. Roth and Mrs. Nancy S. Roth
Mr. Mark Rubin
Mr. Paul Ruchlewicz
S & T Bank
Skip and Gail Sack
Dr. and Mrs. Robert N. Saito
Mr. John Sarto
Mr. Bernard Schiappa
Mr. Mark Schlau
Mr. Leo Schlinkert
Mr. and Mrs. John E. Schlitt
Mr. David Seewack
Sellers Publishing, Inc.
Dr. Brian Shankaruk
Mr. Ralph Shapiro and Ms. Karen Parsons
Mr. and Mrs. John Shaw
Ms. Erika Shields
Mr. Joseph Shiman, III
Mr. E. Michael Shine
Mr. Charles A. Sholtis
Dr. and Ms. Joel Shoolin
Mr. Mark Singer and Mrs. Marci Singer
Mr. Kenneth Sirlin
Mrs. Mary A. Sklenar

Mr. Murray Small and Mrs. Beth Small
Mr. Frank Smiddy and Mrs. Emily Smiddy
Mr. Kenneth Smith
Dr. David Smith
Mr. Kevin Smith
Mr. Vern Smith
Dr. William E. Snowden
Mr. Loren E. Snyder and Mrs. Deborah Snyder
Mr. and Mrs. Michael A. Sommer
Mr. Robert I. Spiegel
Mr. Murray Stark
Mr. George Stark
Mr. Dan Starkey and Mrs. Jenny Starkey
Cora N. Sternberg, M.D.
The Samuel & Barbara Sternberg Charitable Foundation
Mr. Charles Stier
Mr. John Stodola and Ms. Kathleen Frankle
Mr. and Mrs. John Strizver
Ms. Catherine Stupski
Styles of Steppin'
Mr. Ronald Styn and Mrs. Susan C. Styn
Mr. Kevin Sussman
Mr. and Mrs. Richard Szilasi
Mr. and Mrs. John Szoke
Mr. Steven Ta
Mr. Jeff Taarud
Mr. Jon Taggett
Mr. Tony Talbert
Mr. Michael Tang
Mr. Richard A. Tanovich
Ms. Wendy Teramoto
Steve Tino
Ms. Marilyn Titus
Stephen G. Tolchin
Mr. William Tolstyka and Mrs. Katherine Tolstyka
Mr. Pascal F. Tone
Mrs. Teresa Torpey
Mr. Peter L. Townsend
Mr. Scott Turban
Mr. and Mrs. Knight Tuttle
Mr. James Tyler
UGI Energy Services, LLC
Mr. Charles E. Umbarger
Mr. Robert Urban
The Urban Electric Company
Mr. and Mrs. John Veiga
Mr. Jon Visser and Mrs. Robin Visser
Dr. and Mrs. Andrew C. von Eschenbach
Mr. and Mrs. Douglas O. Waikart
Mr. Timothy R. Wallace
Mr. and Mrs. Milton J. Walters
Washington Township Board of Education
Mr. and Mrs. Charles Wax
Mr. Eckard Weber
Michael and Jill Weinstein
Mr. Steven B. Weinstein
Dr. Richard E. Weisblatt
Mr. Paul M. Westbrook
Mr. and Mrs. Nigel Weston
Mr. Howard Wheeler

Martin Wice
Mr. and Mrs. Harry J. Wild
Mr. James S. Williams
Mr. Wayne C. Wilson
The Wilson Sexton Foundation
Mr. Chris Witzany
Mr. Keenan Wolens
Mr. Jon Wolfe
Mr. Stanton Wong
Mr. Roger Wood
Mr. and Mrs. Bruce Wooley
Mr. Jan Yarosz
Mr. and Mrs. Harry Yeaggy
Mr. Robert Zamarripa
Mr. Gary Zellerbach
Mr. Stanley M. Zimmerman and Mrs. Myrna Zimmerman
Mr. David Zinke
Mr. Paul Zoidis and Mrs. Aleta Zoidis

Many vs Cancer Fundraisers

Participants who raised \$1,000 or more

Greg Abbott
Andy Astrachan
Julie Rose Dodson Baisinger
Len Bellavia
Catherina Brown, Styles of Steppin' Seattle
Emilia Clarke
Robert J. Dunne, III
Keith Fanks, Operation Terminate Prostate Cancer
Oliver Freund
Gohill Orthodontics
The Kiat Family
Lakeland Bank
Gideon Lang-Laddie, PROSTATE1000
Matthew Malczewski
Steven Malikowski
Cody Marlatt and the ResearchPoint Global Team
Jennifer Newman, Simon Says Run for Prostate Cancer
Orangetheory Fitness Downtown Sunnyvale and Morgan Hill
Paramus PBA Local 186
Dr. Drew Pinsky
Prior Lake - Savage Area Schools
Muhit Rahman
Melissa Rauch
Alex Rivas & Robin Bunevich
David Seewack
Ramiro Siliezar
Lisa Silver and The Silver Lining
Dr. Jonathan and Plum Simons
Kevin Sussman
Stephen Tendrich, Pink Nail Society
Valley HOG Chapter/McMahon's Harley Davidson
Washington Township Board of Education
Tripp Whitbeck

Blue Ribbon Golf Tournaments

Golf tournaments that raised \$1,000 or more

4th Annual D-III Father's Day Weekend GT
5th Annual 19th Hole Classic
8th Annual C.A.R.E. Golf Outing
8th Annual Jay Moody Memorial
8th Annual Sadie Hawkins GT
10th Annual Pros4Care - Texas
12th Annual HLT Texas Shootout
13th Annual FLHW Golf Tournament
Annual Prostate Cancer Research Invitational
Battle at Addison Reserve
Battle at Bella Vista
Battle at Broken Sound
Battle at Burlington & Rally for the Cure
Battle at Herons Glen
Battle at Katemaya
Battle at the Meadow Club
Battle at Palm Beach
Battle at Pelican Pointe
Battle at Rarity Bay
Breakers MGA Event
Carolina Trace CC MGA Stag Day
Joseph DiNapoli, Sr. Memorial GT
DSB Invitational
El Conquistador Prostate Cancer Tournament
The Hedge Golf Tournament (Shumway Foundation)
Lehigh Valley MGA
Luetzow Charity Golf Outing
Opening Day Golf Tournament
Palm Aire Prostate Tournament
Sheffield Pharma for PC Research
Sweetwater Mens Cancer Tournament
University Park Member-Guest for PCF
Wild Dunes MGA Member/Guest
Willowbrook RCM Memorial
Wycliffe CC MGA

Blue Ribbon Society

Our community of monthly donors

Mr. Steve M. Abbott and Mrs. Diana M. Abbott
Mr. Steven Aberblatt
Mr. Roy E. Acer
Mr. Robert M. Agans
Mr. Larry Aiken
Mr. Mohamed Alhammedi
Mr. Donald Allen
Mr. Dean Ambrose and Mrs. Dianne Ambrose
Mr. Paul N. Anderson
Mr. Paul Anderson
Mr. M. Douglas Archer and Mrs. Pat Archer
Mr. Aaron Bahar
Mr. Louis A. Baldock
Mr. Michael Bankert
Mr. Mark Bass
Mr. Donald Beier

Mr. Dennis E. Bernard
Mr. John P. Bernier and Mrs. Donna Bernier
Mr. Michael Bigini
Mr. Stephen A. Birdsell
Mrs. DeAnna Blankenship
Mr. Robert Blum
Mr. Steve Borowski
Mr. Laurence Brady
Mr. and Mrs. Gerald Brenke
Mr. Robert T. Brew, Jr.
Ms. Renee Bridges
Mr. Kelly Brott
Mr. Grant Brown and Mrs. Sandra Brown
Mr. Scott C. Brown
Mr. and Mrs. Stuart Brown
Mr. Philip Bryan
Mr. Henry L. Burks and Mrs. Diana Burks
Ms. Patricia Burton
Mr. Joe Butler
Mr. and Mrs. Donald Butts
Mr. Danny A. Byler and Mrs. Rose Byler
Mr. Sean Caillias
Mr. Ernest Campos
Frank and Adrienne Cardone
Mr. David P. Carosella
Mr. William Carr and Mrs. Jean Carr
Mr. Howard Chai
Mr. Daniel Chapman
Mr. Steven Chapman
Mr. Scott Chaudoir
Mr. Arthur P. Chimes
Mr. Graham Church
Mr. Matthew Cifichiello
Ms. Dolores Clouser
Mr. Cory Compton and Mrs. Jacqueline Compton
Mr. Clay Cook
Mr. and Mrs. Stephen Cornes
Mr. Craig J. Couture
Mr. Bruce Cox
Mr. Charles E. Cree
Mr. Edgardo Cruz Martinez
Mr. Thomas Czajkowski
Ms. Dorothy Delarm
Mr. Todd J. Dokken
Mr. Don Douglas and Mrs. Carolyne Douglas
Mr. and Mrs. Gary Dummitt
Ms. Sandra Duncan
Mr. Willard Easton and Mrs. Joyce Easton
Eden Formulations
Mr. Kenneth L. English
Mr. and Mrs. Daniel J. Feiner
Mr. Peter Ferrara
Mr. Carlos Ferrer
Mr. Tom Fever
Mr. Arlen J. Fisher
Mr. Greg Fishwick
Dr. Rich Fonda
Mr. Richard Fournier
Mr. Michael R. Franchio and Mrs. Franchio
Mr. Max Fuentes

Mr. Thomas Fuller
 Mr. Ryan Gilmartin
 Mrs. Joyce Gonzales
 Mr. Gary M. Goodfriend
 Mr. Robert Greenbaum and Mrs. Heidi Greenbaum
 Mr. Michael D. Grills
 Ms. Diana Gutkina
 Mr. James G. Hammond
 Ms. Julie A. Hansen
 Mrs. Hope Hare
 Mr. Kent L. Hastings and Mrs. Libby Hastings
 Mr. William R. Hasty and Mrs. Sara Hasty
 Mr. Barry L. Heath
 Ms. Corrie Henderson
 Mr. Joseph Hewell
 Mr. Bradford L. Hillegass
 Mr. Nevin Hoke
 Mr. Robert Horwitz
 Mr. Gary House
 Mr. and Mrs. Michael R. Hund
 Mrs. Christine M. Hunter
 Dr. George Hurwitz and Mrs. Karen Hurwitz
 Lt. Luke W. Jean
 Mr. Alfred John
 Mr. Randall John
 Mr. David Johnson and Mrs. Lynda Johnson
 Mr. Jared Johnson
 Mr. and Mrs. Mark W. Johnson
 Mr. Robert A. Johnson and Mrs. Paula Johnson
 Mr. Roger A. Jones
 Mr. Tom Joplin and Mrs. Shannon Joplin
 Dr. Robert R. Jorgensen and Mrs. Dorothy Jorgensen
 Mrs. Michael I. Joseph
 Mr. Damian J. Kelly
 Dr. David Kenworthy and Mrs. Sharon Kenworthy
 Mr. Joseph Keyes
 Mr. Stephen Kilpatrick
 Dr. Haydn Kissick
 Mr. William D. Kleeman
 Mrs. Mary Kowalski
 Dr. Robert A. Kraft
 Mr. Albert Latini and Mrs. Madelaine Latini
 Mrs. Janet Lehoullier
 Mr. Steven Leonido-John
 Mr. John A. Lever
 Mr. and Mrs. Todd Lewandowski
 Dr. Tom Lewis
 Mr. Robert Lorion
 Mr. Garry Louers, Sr.
 Mr. James MacDonald
 Mrs. Tania J. Malven
 Mr. Jacob Mandel
 Ms. Andrea Marsh
 Mr. David Mason
 Mr. Dean K. Mathis
 Mr. Kenny D. Maynes and Mrs. Maynes
 Mr. Joseph Mazzeo
 Profs. Michael and Kathryn McCarthy
 Capt. William T. McCluskey

Mr. Steven McDonald
 Mr. John Mihalchik
 Mr. Dean Minard
 Ms. Denise Moad Hollingsworth
 Mr. Freeman M. Montaque, Jr.
 Mr. and Mrs. Dennis G. Morgan
 Mr. John E. Moseley and Mrs. R. Victoria Moseley
 Ms. Kathy Nickerson
 Ms. Sarah Noon
 Mr. Francis Jerry Norder
 Mr. Steven Nordstrom
 Mr. Raymond V. O'Connor, Jr.
 Mr. Michael Olds
 Mr. Dennis Ortlund
 Mrs. Mary H. Ott
 Mr. Gregg H. Overman and Mrs. Leona Strizich Overman
 Mr. Thomas Padrick
 Mr. James Paloyan
 Ms. Lisa Palumbo
 Mr. and Mrs. Richard A. Parrish
 Mr. Mark Payton
 Mr. Robert Peach
 Mr. Ronald L. Perry
 Mr. John Plunkett
 Rev. William W. Prior and Mrs. Mary Prior
 Mr. Sachin Purekar
 Mr. Bradley Quale
 Mr. Frank Quale
 Mr. Ben J. Rainbolt
 Mr. Marcio L. Rangel
 Mr. Mark Recouley
 Mr. Gerard Reynolds
 Mr. Riley Rice
 Ms. Kathryn Rittweger
 Mr. and Mrs. Richard Roberson
 Mr. Dan J. Roessner
 Ms. and Dr. Jeanne Rose
 Mr. Kenneth I. Rose, III
 Mr. Rudolf Rottenfusser and Mrs. Hanna Rottenfusser
 Mr. Blair Samuelson
 Mr. Thomas A. Sawyer and Mrs. Susan Sawyer
 Dr. Richard Schatz
 Dr. Michael Scheerer
 Mr. John Schmoltd
 Dr. David M. Shames
 Mr. Robert H. Sherman and Mrs. Corrine Sherman
 Mr. Joseph Shiman, III
 Mr. Derek Simpson
 Dr. Kirk H. Smith
 Mr. Mark C. Smith
 Mr. Mike Smith
 Mr. Lee Stahl
 Mr. Leland L. Stanford
 Mr. and Mrs. William E. Stegall
 Dr. Michael S. Stern and Mrs. Joan Stern
 Lesley and Robert Stern
 Mr. Jeff Strank
 Mr. and Mrs. Donald Stroh
 Mr. Seth Swerdlow
 Mr. and Mrs. Richard Szilasi
 Mr. Richard Taylor

Mr. Paul A. Thiede
 Mr. Charles Thomas
 Mr. Kenneth Thomas
 Ms. Andrea Thompson
 Mr. and Mrs. James E. Thompson
 Mr. Belal M. Tiba
 Mr. George C. Torres and Mrs. Colette Torres
 Mr. Steven L. Trubey
 Mr. Duane E. Trump and Mr. Edan Trump
 Mr. Thomas R. Utesch and Mrs. Jetta Utesch
 Mr. Heinrich Vaseur
 Mr. Michael Vass
 Mr. Demonso A. Waters, Sr.
 Mr. Kevin Webb
 Mr. Jeff Weemhoff
 Mr. Donald Welch
 Mr. Jeff D. Welch
 Mr. Thomas White
 Mr. Drew Whittington
 Mr. Dave Wilder and Mrs. Mary Wilder
 Mr. Lawrence Williams
 Mr. and Mrs. Howard J. Willis
 Mr. Wayne K. Wilson and Mrs. Renate Wilson
 Mr. Ken Wiseman
 Mr. Leslie Wood
 Mr. Robert Yebuah
 Mrs. Darcy Zalewski
 Mr. Jeffrey Zell
 Mr. Felix Zemel
 Mr. Robert F. Zuppert Jr. and Mrs. Emily Zuppert

Memorial Tribute Funds

Funds that contributed \$1,000 or more

In Memory of:

Nathan Baden
 Roddy Brennan
 Daniel J. Brown
 William G. Bryant
 Kent C. Buehner
 Ralph Bushnell
 Steven P. Caley
 Gary Colbert
 Stephen S. Cole
 Jerry J. Commisso
 Larry G. Cornell
 Chuck Crist
 Moti S. Daswani
 Thomas F. Delaney
 Jimmy Ray Dieringer
 Joseph P. DiNapoli
 Bud Dunham
 Harry Falber
 Stuart Flome
 Miles D. Freitag
 Edward Gal
 Harold Gantz
 John G. Gilmour
 Sally Goldman
 Robert E. Goulding
 Leo F. Griffin
 Daryl Gross
 John Haas

Frank J. Heidler
 Thomas Hendricks
 Raymond W. Hine
 Andrew Hruszkewycz
 Thomas E. Jones
 George P. Kelley
 Daniel R. Kramer
 James L. Leachman
 Vincent Lombardi
 David B. Longson
 Chester C. Lucido
 Robert C. Mabry
 Britt M. Moffett
 Ezra Novak
 Anthony L. Pantera
 Mark A. Perrelli
 Harlan Pruger
 Lawrence M. Rhodes
 Alton J. Sadler
 James H. Scheper
 William G. Schmidt
 Douglas H. Simpson
 James T. Sloan
 Reed B. Somberg
 Frederick J. Stabbert
 Richard L. Starkey
 Lawrence J. Stupski
 Tim Taylor
 Robert Temple
 Lawrence Thalmann
 Gary W. Titus
 Jay L. Wallberg
 Jerry Weintraub
 Janet O. White
 Robert H. Young
 David W. Zael

Honorary Tribute Funds

Funds that contributed \$1,000 or more

In Honor of:

Elliot Abramowitz
 Jason Adams
 Andrew J. Astrachan
 Adam P. Dicker
 R. Christian B. Evensen
 Stuart Flome
 Harold Gantz
 Bob Jee
 Gary Lauderdale
 Edward Loftspring
 Earle I. Mack
 Simon McKee
 Michael Milken
 John Milko
 Nelsen Money
 Bonnie L. Pfeifer Evans
 Jonathan W. Simons
 Julius H. Zobel

Represents annual donations (gifts, not pledges) between January 1, 2018 and December 31, 2018.

2018 Research Awards

Expanding PCF's Global Research Enterprise



All attendees present at the 25th Annual PCF Scientific Retreat on Friday, October 26, 2018

PCF YOUNG INVESTIGATOR AWARDS

The achievements of PCF Young Investigators represent some of the most game-changing work in all of cancer research. They keep the field of prostate cancer research vibrant with new ideas. In 2018, PCF funded a Foundation record of 29 new Young Investigators. By mid-year 2018, PCF had funded a total of 255 Young Investigators since the program began in 2007.

2018 Paz Littman & Morris Kahn-PCF Young Investigator Award

Saul AlDubayan, MD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 Clovis Oncology-PCF Young Investigator Award

Mohammad Asim, PhD
University of Surrey, Surrey, England

2018 Lenny Sands-PCF VALor Young Investigator Award

Hala Borno, MD
University of California, San Francisco, San Francisco, CA

2018 Jay Jordan-PCF VALor Young Investigator Award

Frank Cackowski, MD, PhD
University of Michigan, Ann Arbor, MI

2018 Tony D. Minella-PCF VALor Young Investigator Award

Megan Caram, MD
University of Michigan, Ann Arbor, MI

2018 Todd Boehly-PCF Young Investigator Award

Kellie Cotter, PhD
University of Bern, Bern, Switzerland

2018 Jeremy Collier-PCF Young Investigator Award

Anis Hamid, MBBS
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 National Cancer Institute-PCF Young Investigator Award

Jennifer Jones, MD, PhD
National Cancer Institute (NCI), Bethesda, MD

2018 John & Daria Barry Foundation-PCF VALor Young Investigator Award

Salma Kaochar, PhD
Baylor College of Medicine, Houston, TX

2018 Michael & Lori Milken Family Foundation-PCF Young Investigator Award

Sheng-Yu Ku, PhD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 John & Daria Barry Foundation-PCF VALor Young Investigator Award

Hui Li, PhD
University of California, San Francisco, San Francisco, CA

2018 ASTRO-PCF Career Development Award to End Prostate Cancer

Brandon Mahal, MD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 Thomas H. Lee-PCF VALor Young Investigator Award

Danil Makarov, MD
New York University, New York, NY

2018 Thomas Finke-PCF VALor Young Investigator Award

Megan McNamara, MD
Duke University, Durham, NC

2018 Rebecca and Nathan Milikowsky-PCF Young Investigator Award

Kent Mouw, MD, PhD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 James Maguire-PCF Young Investigator Award

Vivek Narayan, MD
University of Pennsylvania, Philadelphia, PA

2018 John & Daria Barry Foundation-PCF VALor Young Investigator Award

David Oh, MD, PhD
University of California, San Francisco, San Francisco, CA

2018 Foundation 14-PCF Young Investigator Award

Eileen Parkes, MD, PhD
Queen's University Belfast, Belfast, Northern Ireland

2018 Gina Rinehart-PCF Young Investigator Award

Raquel Perez-Lopez, MD, PhD
Vall d'Hebron Institute of Oncology, Barcelona, Spain

2018 PCF VALor Young Investigator Award

Year 1 – Keith Frankel
Year 2 – Michael DeAddio
Year 3 – Thomas H. Lee
Sethuramasundaram Pitchiaya, PhD
University of Michigan, Ann Arbor, MI

2018 Seth Bernstein-PCF Young Investigator Award

Nicholas Reder, MD, MPH
University of Washington, Seattle, WA

2018 Igor Tulchinsky-PCF VALor Young Investigator Award

Zachery Reichert, MD, PhD
University of Michigan, Ann Arbor, MI

2018 Clay Hamlin-PCF Young Investigator Award in Honor of H. Ward Hamlin, Jr.

Veronica Rodriguez-Bravo, PhD
Thomas Jefferson University, Philadelphia, PA

2018 Michael & Lori Milken Family Foundation-PCF Young Investigator Award

Joshua Russo, MD, PhD
Harvard: Beth Israel Deaconess Medical Center, Boston, MA

2018 Larry Ruvo-PCF Young Investigator Award

Adam Sharp, MD, PhD
Institute of Cancer Research, The Royal Marsden Hospital, London, England

2018 PCF Young Investigator Award in Honor of Selma Rabin

Min Yuen Teo, MD
Memorial Sloan Kettering Cancer Center, New York, NY

2018 Seth Bernstein-PCF Young Investigator Award

Vasanthi Viswanathan, PhD
Broad Institute of MIT & Harvard, Cambridge, MA

2018 National Cancer Institute-PCF Young Investigator Award

Scott Wilkinson, PhD
National Cancer Institute, Bethesda, MD

2018 John & Daria Barry Foundation-PCF VALor Young Investigator Award

David Wise, MD, PhD
New York University, New York, NY

2016 Michael DeAddio-PCF Young Investigator Award (Funding Year 3 of 3)

Alastair Davies, PhD
University of British Columbia, Vancouver, BC

2016 Adrienne and Jerry Cohen-PCF Young Investigator Award (Funding Year 3 of 3)

Eleonora Dondossola, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX



All PCF Young Investigators present at the 25th Annual PCF Scientific Retreat

PCF CHALLENGE AWARDS

In 2018, 20 Challenge Award teams were funded by the Foundation. Through peer reviews, PCF selected these projects out of 70 proposals from highly qualified research teams at 48 prestigious cancer centers located in 9 countries. The Class of 2018 Challenge Awards represents an investment of nearly \$17 million in advanced prostate cancer research.

2018 Movember Foundation–PCF Challenge Awards

Co-Principal Investigators:

Mark Pomerantz, MD

Harvard: Dana-Farber Cancer Institute, Boston, MA

Philip Kantoff, MD

Memorial Sloan Kettering Cancer Center, New York, NY

Goal: *To determine the prevalence and prognostic significance of inherited DNA Damage Repair gene alterations in high-risk localized prostate cancer, and model the impact of germline screening and risk-tailored management in this population*

2018 Movember Foundation–PCF VALor Challenge Award

Co-Principal Investigators:

Julie Graff, MD

VA Portland Healthcare System, Portland, OR

Amy Moran, PhD

Oregon Health & Science University, Portland, OR

Karen Sfanos, PhD

Johns Hopkins University, Baltimore, MD

Goal: *To conduct a clinical trial testing a therapy targeting TROP-2 and develop biomarkers to select patients likely to benefit*

2018 Movember Foundation–PCF VALor Challenge Award

Co-Principal Investigators:

Steven Patierno, PhD

Duke University, Durham, NC

Daniel George, MD

Duke University, Durham, NC

Jennifer Freedman, PhD

Duke University, Durham, NC

Jiaoti Huang, MD, PhD

Duke University, Durham, NC

Amanda Hargrove, PhD

Duke University, Durham, NC

Goal: *To determine whether altered RNA splicing drives more aggressive prostate cancer in African American men, and the therapeutic potential for targeting this biology*

2018 Movember Foundation / Distinguished Gentleman's Ride–PCF VALor Challenge Award

Co-Principal Investigators:

Susan Halabi, PhD

Duke University, Durham, NC

Christopher Sweeney, MBBS

Harvard: Dana-Farber Cancer Institute, Boston, MA

Jayne Tierney, PhD

University College London Cancer Institute, London, England

Goal: *To identify intermediate clinical endpoints that reliably predict overall survival in men with metastatic hormone sensitive prostate cancer, in order to speed and improve clinical trials*

2018 PCF Challenge Awards

Co-Principal Investigators:

Emmanuel Antonarakis, MD

Johns Hopkins University, Baltimore, MD

Sushant Kachhap, PhD

Johns Hopkins University, Baltimore, MD

Goal: *To evaluate the efficacy of bipolar androgen therapy followed by immunotherapy in advanced prostate cancer patients, and define biomarkers and mechanisms of response*

Award Donor: The Morris & Alma Schapiro Fund

Co-Principal Investigators:

Steven Balk, MD, PhD

Harvard: Beth Israel Deaconess Medical Center, Boston, MA

Huihui Ye, MD

Harvard: Beth Israel Deaconess Medical Center, Boston, MA

David Avigan, MD

Harvard: Beth Israel Deaconess Medical Center, Boston, MA

Gordon Freeman, PhD

Harvard: Dana-Farber Cancer Institute, Boston, MA

Goal: *To develop biomarkers that predict responsiveness to checkpoint immunotherapy, and identify mutated tumor proteins that have potential as tumor vaccine targets*

Award Donors: Stewart J. Rahr Foundation and various other donors

Co-Principal Investigators:

George Coukos, MD, PhD

University of Lausanne, Lausanne, Switzerland

Mark Rubin, MD

University of Bern, Bern, Switzerland

Goal: *To investigate whether radiation therapy can improve responses to checkpoint immunotherapy in prostate cancer, and develop biomarkers to identify patients likely to benefit from this combination*

Award Donor: Stewart J. Rahr Foundation

Co-Principal Investigators:

Claire Fletcher, PhD

Imperial College London, London, England

Charlotte Bevan, PhD

Imperial College London, London, England

Goal: *To determine whether the genome-protecting RNA NORAD may serve as a new treatment target and as a biomarker to predict treatment responses*

Award Donor: John Black Charitable Foundation

Co-Principal Investigators:

Rakesh Heer, MBBS, PhD

Newcastle University, Newcastle upon Tyne, England

Luke Gaughan, PhD

Newcastle University, Newcastle upon Tyne, England

Goal: *To develop a prostate cancer organoid model system that recreates tumor mutations from individual patients and aids in selecting precision medicine treatments*

Award Donors: John Black Charitable Foundation, John Drew

Co-Principal Investigators:

Philip Kantoff, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Lorelei Mucci, ScD, MPH
Harvard T.H. Chan School of Public Health, Boston, MA
Elli Papaemmanuil, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Berger, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
Ross Levine, MD
Memorial Sloan Kettering Cancer Center, New York, NY

Goal: *To determine whether clonal hematopoiesis, a condition characterized by the accumulation of mutations in blood cells, promotes worse outcomes in prostate cancer patients and influences the efficacy or toxicity of treatments*

Award Donor: Anonymous

Co-Principal Investigators:

Aaron LeBeau, PhD
University of Minnesota, Minneapolis, MN
Brandon Moriarty, PhD
University of Minnesota, Minneapolis, MN
Charles Ryan, MD
University of Minnesota, Minneapolis, MN
Todd DeFor, MS
University of Minnesota, Minneapolis, MN
Jeffrey Miller, MD
University of Minnesota, Minneapolis, MN

Goal: *To develop a novel CD133-targeted NK cell immunotherapy for the treatment of aggressive variant prostate cancer*

Award Donors: Anonymous, The Lawrence R. Souza Revocable Living Trust, Foundation 14

Co-Principal Investigators:

Douglas McNeel, MD, PhD
University of Wisconsin, Madison, WI
Jamey Weichert, PhD
University of Wisconsin, Madison, WI

Goal: *To investigate the efficacy of combining checkpoint immunotherapy, anti-tumor vaccines, and targeted radionuclide therapy for the treatment of prostate cancer*

Award Donors: Janssen Pharmaceuticals and anonymous donor

Principal Investigators:

Kenneth Pienta, MD
Johns Hopkins University, Baltimore, MD
Johann de Bono, MD, PhD
Institute of Cancer Research, The Royal Marsden Hospital, London, England
Peter Kuhn, PhD
University of Southern California, Los Angeles, CA
Bruce Trock, PhD, MPH
Johns Hopkins University, Baltimore, MD
Tamara Lotan, MD
Johns Hopkins University, Baltimore, MD
Jun Luo, PhD
Johns Hopkins University, Baltimore, MD

Goal: *To develop biomarkers for early identification of prostate cancer patients at risk for lethal disease and determine the steps by which prostate cancer metastasizes*

Award Donors: David Fleischer and various other donors

Co-Principal Investigators:

Ganesh Raj, MD, PhD
University of Texas Southwestern Medical Center, Dallas, TX
Xiankai Sun, PhD
University of Texas Southwestern Medical Center, Dallas, TX

Goal: *To develop novel drugs for neuroendocrine prostate cancer which can simultaneously be used for both imaging and treatment*

Award Donors: The Lawrence R. Souza Revocable Living Trust, Jeff Zisk

2018 PCF VALor Challenge Awards

Co-Principal Investigators:

Thomas Hope, MD
University of California, San Francisco, San Francisco, CA
Matthew Rettig, MD
University of California, Los Angeles, Los Angeles, CA
Michael Morris, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Matthias Eiber, MD
Technical University of Munich, Munich, Germany

Goal: *To determine factors associated with response to PSMA-targeted radionuclide therapy and improve selection of patients most likely to benefit from this treatment*

Award Donors: Peter Grauer, Michael Berns, Michael DeAddio, Randy King

Principal Investigator:

Nima Sharifi, MD
Cleveland Clinic Foundation, Cleveland, OH

Goal: *To determine the mechanisms by which the glucocorticoid receptor pathway can drive resistance to androgen receptor-targeted therapies, and develop new treatments to target this pathway*

Award Donor: Larry Mizel

Co-Principal Investigators:

Michael Shen, PhD
Columbia University Medical Center, New York, NY
Charles Drake, MD, PhD
Columbia University Medical Center, New York, NY
Andrea Califano, PhD
Columbia University Medical Center, New York, NY

Goal: *To identify and validate individualized treatments that target novel prostate cancer drivers in the tumor microenvironment*

Award Donor: Stewart J. Rahr Foundation

2018 PCF Special Challenge Awards

Co-Principal Investigators:

Howard Scher, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Dana Tsui, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
Patrick Erdman, DO
Memorial Sloan Kettering Cancer Center, New York, NY

Goal: *To investigate the impact of various blood collection methods and patient factors on results from liquid biopsy tests in order to accelerate the development of prostate cancer precision medicine tests that can be used in routine practice settings*

Award Donor: Stewart J. Rahr Foundation

PCF AttackJAK Special Challenge Award

Principal Investigator:

Ross Levine, MD
Memorial Sloan Kettering Cancer Center, New York, NY

Goal: *Development and validation of JAK2 kinase inhibitors as a novel cancer treatment*

Award Donor: Arthur Kern

The ICECaP Initiative: Assessment of Intermediate Clinical Endpoints

Principal Investigator:

Christopher Sweeney, MBBS
Harvard: Dana-Farber Cancer Institute

Goal: *To identify intermediate clinical endpoints that serve as reliable surrogates for overall survival in localized prostate cancer clinical trials in order to accelerate the development of new treatments for these patients*

Award Donors: Dendreon and Sanofi Genzyme

PCF VALOR PRECISION ONCOLOGY CENTER OF EXCELLENCE AWARDS

As of October 2018, 10 Precision Oncology Centers of Excellence were funded by the Foundation through PCF's now 2-year partnership with the U.S. Veterans Administration. The Class of 2018 PCF-VALor Centers of Excellence Awards represents a commitment of \$25.5 million over 5 years to provide U.S. veterans with the same or better precision oncology care and the same access to clinical trials as our most fortunate private citizens.

The 2018 Stewart J. Rahr Foundation Precision Oncology Center of Excellence Award

Principal Investigator:

Ajjai Alva, MD

VA Ann Arbor Healthcare System / University of Michigan, Ann Arbor, MI

The Blavatnik Family Foundation Precision Oncology Center of Excellence Award

Principal Investigator:

Antonio Fojo, MD, PhD

James J. Peters VA Medical Center / Columbia University Medical Center, Bronx, NY

The Robert Frederick Smith Precision Oncology Center of Excellence Award

Principal Investigator:

Joshua Meeks, MD, PhD

Jesse Brown VA Medical Center / Northwestern University, Chicago, IL

The Stephen J. Cloobek Precision Oncology Center of Excellence Award

Principal Investigator:

Robert Bruce Montgomery, MD

VA Puget Sound Health Care System / University of Washington, Seattle, WA

The John and Daria Barry Foundation Precision Oncology Center of Excellence Award

Principal Investigator:

Danil Makarov, MD

VA New York Harbor Healthcare System / New York University, Manhattan, NY

The Lori and Michael Milken Family Foundation Precision Oncology Center of Excellence Award

Principal Investigator:

Matthew Rettig, MD

VA West Los Angeles Medical Center / University of California, Los Angeles, Los Angeles, CA

The Trailsend Foundation and Elaine Wynn Precision Oncology Center of Excellence Award

Principal Investigator:

Megan McNamara, MD

Durham VA Medical Center / Duke University, Durham, NC

The Andy Astrachan and Marc Utay Precision Oncology Center of Excellence Award

Principal Investigators:

Kyle Robinson, MD

Corporal Michael J. Crescenz VA Medical Center / University of Pennsylvania, Philadelphia, PA

Nevena Damjanov, MD


Corporal Michael J. Crescenz VA Medical Center / University of Pennsylvania, Philadelphia, PA

The John and Daria Barry Foundation Precision Oncology Center of Excellence Award

Principal Investigator:

Kosj Yamoah, MD, PhD

VA Sunshine Healthcare Network, Tampa, FL / H. Lee Moffitt Cancer Center & Research Institute, St. Petersburg, FL



ANNUAL PCF WOMEN IN SCIENCE FORUM

The Prostate Cancer Foundation is acknowledging the amazing contributions that women have made in the field of science and medicine, specifically in prostate cancer research.

Before PCF began to encourage prostate cancer researchers by funding their early careers, the numbers of women in the field were few. Through our Young Investigator Awards and team science Challenge Awards programs, PCF has helped to increase the number of women who are building a long-term career in prostate cancer research.

“The Prostate Cancer Foundation has really led the effort in supporting women in science,” said PCF Young Investigator Stacy Loeb, MD, of New York University.



The prostate cancer field has historically been male-dominated. Beginning in 2016, in recognition of career issues unique to women, three female PCF-funded investigators, Drs. Karen Knudsen, PhD (Thomas Jefferson University), Lorelei Mucci, ScD (Harvard School of Public Health), and Himisha Beltran, MD (Weill Cornell Medicine), organized a PCF Women in Science Forum at PCF's Annual Scientific Retreat, to which all female (and any interested male) attendees are invited to attend. The goals of the Forum are to create a network of PCF-funded women scientists, to team-build through discussion and social events, to ensure a strong pipeline of female prostate cancer researchers and clinicians, and to identify opportunities for further training, mentoring, and synergy of a stellar network of female prostate cancer researchers and clinicians.



Attendees of the 3rd Annual PCF Women in Science Forum during PCF's 25th Annual Scientific Retreat in October 2018.

Consolidated Statement of Financial Position

December 31	Without Donor Restrictions	With Donor Restrictions	2018 Total	2017 Total
ASSETS				
Cash and Cash Equivalents	\$ 16,044,813	\$ 4,650,000	\$ 20,694,813	\$ 24,166,964
Pledges Receivable (Net)	14,894,136	12,725,000	27,619,136	27,596,425
Prepaid Expenses and Other Assets	1,009,073	-	1,009,073	1,135,934
Property and Equipment (Net)	1,660,133	-	1,660,133	1,865,740
Total Assets	\$ 33,608,155	\$ 17,375,000	\$ 50,983,155	\$ 54,765,063
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts Payable	\$ 783,154	\$ -	\$ 783,154	\$ 1,319,780
Accrued Liabilities	2,298,474	-	2,298,474	1,916,705
Deferred Revenue	50,000	-	50,000	100,000
Grants Payable	22,589,282	-	22,589,282	22,612,846
Total Liabilities	25,720,910	-	25,720,910	25,949,331
Net Assets				
Without Donor Restrictions	7,887,245	-	7,887,245	17,982,398
With Donor Restrictions	-	17,375,000	17,375,000	10,833,334
Total Net Assets	7,887,245	17,375,000	25,262,245	28,815,732
Total Liabilities and Net Assets	\$ 33,608,155	\$ 17,375,000	\$ 50,983,155	\$ 54,765,063

Consolidated Statement of Activities

Year Ended December 31	Without Donor Restrictions	With Donor Restrictions	2018 Total	2017 Total
Revenue and Public Support				
Grants and Contributions	\$ 28,693,134	\$ 13,375,000	\$ 42,068,134	\$ 44,056,615
Interest and Dividends	232,741	-	232,741	88,679
Other Income (Loss)	(274,082)	-	(274,082)	(327,539)
Net Assets Released from Donor Restrictions	6,833,334	(6,833,334)	-	-
Total Revenue and Public Support	35,485,127	6,541,666	42,026,793	43,817,755
Expenses				
Program Services:				
Research Grants	28,275,948	-	28,275,948	27,813,385
Compensation, Benefits, and Payroll Taxes	3,972,609	-	3,972,609	3,772,146
Global Scientific Conferences, Unpublished Data, and Knowledge Exchanges	2,091,212	-	2,091,212	1,991,482
Professional Fees	895,647	-	895,647	778,077
Outreach, Events, and Meetings	882,407	-	882,407	369,934
Media, Public Relations, and Publications	788,133	-	788,133	941,673
Depreciation and Amortization	466,852	-	466,852	380,396
Travel, Meals, and Entertainment	335,641	-	335,641	265,805
Office Expenses	228,654	-	228,654	204,113
Occupancy	180,390	-	180,390	165,074
Total Program Services:	38,117,493	-	38,117,493	36,682,085
Supporting Services:				
Management and General:				
Compensation, Benefits, and Payroll Taxes	1,983,550	-	1,983,550	1,997,020
Office Expenses	858,766	-	858,766	720,302
Professional Fees	411,229	-	411,229	380,260
Occupancy	164,525	-	164,525	164,195
Travel, Meals, and Entertainment	72,596	-	72,596	119,105
Depreciation and Amortization	71,296	-	71,296	30,553
Media, Public Relations, and Publications	30,073	-	30,073	48,268
Other Expenses	-	-	-	30,000
Total Management and General:	3,592,035	-	3,592,035	3,489,703
Fundraising:				
Outreach, Events, and Meetings	1,659,027	-	1,659,027	2,683,645
Travel, Meals, and Entertainment	1,109,413	-	1,109,413	1,315,149
Compensation, Benefits, and Payroll Taxes	532,810	-	532,810	529,659
Office Expenses	380,177	-	380,177	361,721
Professional Fees	157,198	-	157,198	251,281
Occupancy	22,322	-	22,322	35,376
Depreciation and Amortization	8,682	-	8,682	2,256
Media, Public Relations, and Publications	1,123	-	1,123	3,999
Total Fundraising:	3,870,752	-	3,870,752	5,183,086
Total Expenses	45,580,280	-	45,580,280	45,354,874
Change in Net Assets	(10,095,153)	6,541,666	(3,553,487)	(1,537,119)
Net Assets – Beginning of Year	17,982,398	10,833,334	28,815,732	30,352,851
Net Assets – End of Year	\$ 7,887,245	\$ 17,375,000	\$ 25,262,245	\$ 28,815,732

Consolidated Statement of Cash Flows

Year Ended December 31	2018	2017
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in Net Assets	\$ (3,553,487)	\$ (1,537,119)
Adjustments to Reconcile Change in Net Assets to Net Cash Used In Operating Activities:		
Uncollectible Pledges Receivable	-	30,000
Change in Present Value Discount on Pledges Receivable	415,854	94,086
Depreciation and Amortization	546,830	413,205
(Increase) Decrease in:		
Pledges Receivable	(438,565)	730,535
Prepaid Expenses and Other Assets	126,861	(932,453)
Increase (Decrease) in:		
Accounts Payable	(536,626)	589,198
Accrued Liabilities	381,769	552,179
Deferred Revenue	(50,000)	(100,000)
Grants Payable	(23,564)	2,170,608
Net Cash Provided by (Used In) Operating Activities	(3,130,928)	2,010,239
CASH FLOWS USED IN INVESTING ACTIVITIES:		
Purchase of Property and Equipment:	(341,223)	(1,569,207)
Net Increase/(Decrease) in Cash and Cash Equivalents	(3,472,151)	441,032
Cash and Cash Equivalents – Beginning of Year	24,166,964	23,725,932
Cash and Cash Equivalents – End of Year	\$ 20,694,813	\$ 24,166,964

Independent Auditor's Report

To the Board of Directors
Prostate Cancer Foundation

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of the Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2018, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Prostate Cancer Foundation as of December 31, 2018, and the changes in its consolidated net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information

We have previously audited Prostate Cancer Foundation's 2017 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated August 15, 2018. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2017 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Green Hasson & Janks LLP

April 8, 2019
Los Angeles, California

2018 Supporting Partners

PCF is grateful for our corporate supporters. Contributions and campaigns from these organizations are enabling PCF to move closer to a world without prostate cancer.



Board of Directors and Leadership Team

Board of Directors

Michael Milken
Founder and Chairman
Prostate Cancer Foundation

Andrew J. Astrachan
Chief Executive Officer
Onyx Partners, Inc.

Emilio Bassini
Managing Principal
Bassini & Company

James C. Blair, PhD
Partner
Domain Associates, LLC

Steven A. Burd
Founder and Chief Executive
Officer
Burd Health LLC

Neil P. DeFeo
Executive Partner
Nonantum Capital Partners

David A. Ederer
Chairman
Ederer Investment Company

Jonathan Evans
President
Evans & Co., LLC

R. Christian B. Evensen
Managing Partner
Flintridge Capital
Investments, LLC

Peter T. Grauer
Chairman
Bloomberg LP

The Reverend Rosey Grier
Milken Family Foundation

Stein Erik Hagen
Chairman
Orkla ASA

Stuart Holden, MD
Clinical Professor of Urology
David Geffen School of Medicine,
Spielberg Family Chair of Urologic
Oncology,
Associate Director, UCLA Institute
of Urologic Oncology

Clark Howard
Syndicated TV and Radio Host

Arthur H. Kern
Investor

David H. Koch
Board Director
Koch Industries, Inc.

The Honorable Earle I. Mack
Senior Partner
The Mack Company

Shmuel Meitar
Chairman and Founder
Aurec Capital

Lori Milken
Vice President
Prostate Cancer Foundation

Christopher J. Moran
Chairman
Moran Group of Companies
Chairman
Co-Operation Ireland

Henry L. Nordhoff
Chairman and
Chief Executive Officer
Banyan Biomarkers, Inc.

Drew Pinsky, MD
Internist, Addictionologist,
Radio and Television Host

Lynda Resnick
Vice Chairman
The Wonderful Company

Neal I. Rodin
Chairman
International Financial
Company, LLC
Chairman
RREI, LLC

Jason J. Safriet
Managing Director
Head of Security Sales
Credit Suisse

Richard V. Sandler
Partner
Maron & Sandler
Executive Vice President
Milken Family Foundation

Paul Villanti
Executive Director, Programs
Movember Foundation

Andrew C. von Eschenbach, MD
President, Samaritan Health
Initiatives Inc.
Former Commissioner, Food and
Drug Administration
Former Director, National Cancer
Institute
Senior Fellow, Milken Institute

Kneeland Youngblood, MD
Founding Partner
Pharos Capital Group

Jeff Zisk
Managing Director
Surrey Ventures

Leadership Team

Jonathan W. Simons, MD
President and
Chief Executive Officer

Ralph Finerman
Chief Financial Officer,
Treasurer, and Secretary

Howard R. Soule, PhD
Executive Vice President,
Chief Science Officer

Stuart Holden, MD
Medical Director

Christine N. Jones
Chief Operating Officer

Helen Hsieh
Senior Vice President
Finance and Administration

Ed Dean
Vice President
Corporate Development

Benjamin Engel
Vice President
Development Operations

Jan Haber
Vice President
Events

Julie DiBiase
Vice President
Content

Colleen McKenna
Vice President
Communications and Public
Relations

Rebecca Levine
Chief of Staff, Vice President,
Government Affairs

Kathryn Schwertfeger
General Counsel



PCF Congratulates and Commends

James P. Allison, PhD 2018 Recipient of the Nobel Prize in Medicine for Immunotherapy

James Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, was awarded the 2018 Nobel Prize in Physiology or Medicine for launching an effective new way to attack cancer by treating the immune system rather than the tumor. The prize recognizes Allison's basic science discoveries on the biology of T cells, the adaptive immune system's soldiers, and his invention of immune checkpoint blockade to treat cancer.

PCF is extremely proud to have provided crucial, initial funding for Dr. Allison's early prostate cancer immunotherapy research.

The Nobel Prize in Physiology or Medicine has been awarded 108 times to 214 Nobel Laureates between 1901 and 2017.

